Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,900 | 2019-08-27 00:00:00 UTC | Should You Buy AbbVie for the Dividend? | ABBV | https://www.nasdaq.com/articles/should-you-buy-abbvie-for-the-dividend-2019-08-27 | null | null | AbbVie Inc (NYSE: ABBV) has been on a downward spiral since early 2018. Year to date, the company's share price has decreased by about 26%. This prolonged slump is unprecedented for AbbVie, at least since the firm spun off from Abbott Laboratories (NYSE: ABT). Despite these headwinds, it is hard to ignore AbbVie's stel... | Though Humira has been AbbVie's top selling drug for a while -- spearheading the firm's revenue growth -- it is now facing stiff competition in Europe. Synergy issues between the two companies aside, detractors will argue that Allergan suffers from the same problem that has plagued AbbVie: an over reliance on one produ... | US sales of Humira increased by about 8% during AbbVie's second quarter, but its international sales decreased by 35%, resulting in a net decrease of 6% year over year. AbbVie Inc (NYSE: ABBV) has been on a downward spiral since early 2018. This prolonged slump is unprecedented for AbbVie, at least since the firm spun ... | US sales of Humira increased by about 8% during AbbVie's second quarter, but its international sales decreased by 35%, resulting in a net decrease of 6% year over year. AbbVie merges with Allergan Perhaps the biggest move AbbVie made recently was its blockbuster merger with Allergan (NYSE: AGN) in a cash-and-stock deal... | US sales of Humira increased by about 8% during AbbVie's second quarter, but its international sales decreased by 35%, resulting in a net decrease of 6% year over year. Clearly, AbbVie isn't for every investor, but with a (relatively) attractive future earnings potential, the pharma company still looks like an excellen... |
24,901 | 2019-08-25 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2019-08-25 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the biggest cancer drugs in the world. At the same time, the two pharmaceutical companies compete tooth-and-nail against each other in the immunology market.
J&J has been the bigger winner so far in 2019 even with its stock down slightly year to da... | The deal will enable AbbVie to gain a lineup including blockbuster drug Botox and promising eye-disease candidate abicipar. With its super-high dividend yield, AbbVie doesn't have to deliver much growth in its share price for investors to enjoy solid total returns. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) ... | The case for AbbVie AbbVie has known for years that sales for its blockbuster immunology drug, Humira, would one day begin to slip. With its super-high dividend yield, AbbVie doesn't have to deliver much growth in its share price for investors to enjoy solid total returns. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYS... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the biggest cancer drugs in the world. The case for AbbVie AbbVie has known for years that sales for its blockbuster immunology drug, Humira, would one day begin to slip. That's because AbbVie's shares have plunged nearly 30% as investors worry abo... | The case for AbbVie AbbVie has known for years that sales for its blockbuster immunology drug, Humira, would one day begin to slip. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the biggest cancer drugs in the world. That's because AbbVie's shares have plunged nearly 30% as investors worry abo... |
24,902 | 2019-08-20 00:00:00 UTC | IXJ, LLY, ABBV, DHR: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ixj-lly-abbv-dhr%3A-large-outflows-detected-at-etf-2019-08-20 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $52.0 million dollar outflow -- that's a 2.4% decrease week over week (from 35,750,000 to 34,900,000). Among... | Among the largest underlying components of IXJ, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 2.1%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IXJ, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 2.1%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IXJ, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 2.1%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of IXJ, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 2.1%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... |
24,903 | 2019-08-20 00:00:00 UTC | AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira | ABBV | https://www.nasdaq.com/articles/abbvies-latest-fda-approval-is-its-most-important-immunology-win-since-humira-2019-08-20 | null | null | You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least when it comes to winning drug approvals. Since the beginning of 2019, the big biotech has racked up U.S. Food and Drug Administration (FDA) approvals for a combination of Imbruvica and Gazyva in treating chronic lymphocytic leukemia/small l... | AbbVie announced results last year from the Select-Compare phase 3 clinical study evaluating Rinvoq versus Humira in treating rheumatoid arthritis. AbbVie is also evaluating Rinvoq in late-stage clinical studies targeting atopic dermatitis, Crohn's disease, giant cell arteritis, psoriatic arthritis, and ulcerative coli... | AbbVie announced results last year from the Select-Compare phase 3 clinical study evaluating Rinvoq versus Humira in treating rheumatoid arthritis. You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least when it comes to winning drug approvals. On Friday, AbbVie added another key FDA approval wi... | AbbVie announced results last year from the Select-Compare phase 3 clinical study evaluating Rinvoq versus Humira in treating rheumatoid arthritis. However, Rinvoq appears very likely to become AbbVie's biggest immunology drug after Humira. You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least... | On Friday, AbbVie added another key FDA approval with a positive decision for Rinvoq (upadacitinib) in treating rheumatoid arthritis. You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least when it comes to winning drug approvals. This latest FDA approval is AbbVie's biggest regulatory victory s... |
24,904 | 2019-08-19 00:00:00 UTC | 5 Biggest New Drug Approvals Potentially on the Way in 2019 | ABBV | https://www.nasdaq.com/articles/5-biggest-new-drug-approvals-potentially-on-the-way-in-2019-2019-08-19 | null | null | AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) scored key drug approvals by the U.S. Food and Drug Administration (FDA) earlier this year. Each of the two companies landed products in market researcher EvaluatePharma's top-five list of the biggest new drugs approved so far in 2019.
But what about important FDA approvals ... | AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) scored key drug approvals by the U.S. Food and Drug Administration (FDA) earlier this year. AbbVie and Novartis made this list, too. Upadacitinib EvaluatePharma ranked AbbVie's Skyrizi as the No. | AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) scored key drug approvals by the U.S. Food and Drug Administration (FDA) earlier this year. AbbVie and Novartis made this list, too. Upadacitinib EvaluatePharma ranked AbbVie's Skyrizi as the No. | AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) scored key drug approvals by the U.S. Food and Drug Administration (FDA) earlier this year. Another immunology drug from AbbVie, upadacitinib, took the top spot on the market researcher's list of the biggest new drug approvals on the way. AbbVie and Novartis made this list, ... | AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) scored key drug approvals by the U.S. Food and Drug Administration (FDA) earlier this year. AbbVie and Novartis made this list, too. Upadacitinib EvaluatePharma ranked AbbVie's Skyrizi as the No. |
24,905 | 2019-08-15 00:00:00 UTC | 13 High-Yield Dividend Stocks to Watch | ABBV | https://www.nasdaq.com/articles/13-high-yield-dividend-stocks-to-watch-2019-08-15 | null | null | High-yield dividend stocks have gained even more allure lately in the face of shrinking bond yields. However, while a handful are ready buys right now, several more sport alluring yields - at least 5%, and up into the double digits - but need a little more time to simmer before it's time to dip in.
Patience is a virtue... | SEE ALSO: The 13 Best REITs to Buy in 2019 AbbVie Market value: $93.5 billion Dividend yield: 6.7% Pharmaceuticals are a tough business these days. Not surprisingly, AbbVie (ABBV, $63.50) has had a rough ride. AbbVie trades at a ridiculously cheap 6.9 times forward earnings. | SEE ALSO: The 13 Best REITs to Buy in 2019 AbbVie Market value: $93.5 billion Dividend yield: 6.7% Pharmaceuticals are a tough business these days. Not surprisingly, AbbVie (ABBV, $63.50) has had a rough ride. AbbVie trades at a ridiculously cheap 6.9 times forward earnings. | SEE ALSO: The 13 Best REITs to Buy in 2019 AbbVie Market value: $93.5 billion Dividend yield: 6.7% Pharmaceuticals are a tough business these days. Not surprisingly, AbbVie (ABBV, $63.50) has had a rough ride. AbbVie trades at a ridiculously cheap 6.9 times forward earnings. | SEE ALSO: The 13 Best REITs to Buy in 2019 AbbVie Market value: $93.5 billion Dividend yield: 6.7% Pharmaceuticals are a tough business these days. Not surprisingly, AbbVie (ABBV, $63.50) has had a rough ride. AbbVie trades at a ridiculously cheap 6.9 times forward earnings. |
24,906 | 2019-08-14 00:00:00 UTC | Oversold Conditions For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/oversold-conditions-for-abbvie-abbv-2019-08-14 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $63.50 per share. A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, an... | A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in i... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $63.50 per share. A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, an... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $63.50 per share. A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, an... |
24,907 | 2019-08-13 00:00:00 UTC | 5 Biggest New Drugs Approved in 2019 So Far | ABBV | https://www.nasdaq.com/articles/5-biggest-new-drugs-approved-in-2019-so-far-2019-08-13 | null | null | Biopharmaceutical investors like blockbuster drugs. And so far in 2019, there have been several new drugs to enter the market that hold the potential to generate $1 billion or more in annual sales over the next few years.
Market researcher EvaluatePharma recently issued its half-year report that ranked the biggest new ... | AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) each claimed at least one drug on the list. Skyrizi AbbVie's Skyrizi landed at No. AbbVie launched the drug in May with a list price of $59,000. | AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) each claimed at least one drug on the list. Skyrizi AbbVie's Skyrizi landed at No. AbbVie launched the drug in May with a list price of $59,000. | AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) each claimed at least one drug on the list. If Skyrizi racks up annual sales of $3.2 billion within the next five years as EvaluatePharma projects, the drug's sales would represent nearly 10% of AbbVie's 2018 revenue. Skyri... | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) each claimed at least one drug on the list. Skyrizi AbbVie's Skyrizi landed at No. |
24,908 | 2019-08-12 00:00:00 UTC | SDY, AMCA: Big ETF Outflows | ABBV | https://www.nasdaq.com/articles/sdy-amca%3A-big-etf-outflows-2019-08-12 | null | null | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the SPDR S&P Dividend ETF (SDY), where 13,200,000 units were destroyed, or a 6.7% decrease week over week. Among the largest underlying components of SDY, in morning trading today AT&T ... | Among the largest underlying components of SDY, in morning trading today AT&T (T) is off about 0.1%, and Abbvie (ABBV) is lower by about 0.8%. And on a percentage change basis, the ETF with the biggest outflow was the iShares Russell 1000 Pure U.S. Revenue ETF (AMCA), which lost 150,000 of its units, representing a 37.... | Among the largest underlying components of SDY, in morning trading today AT&T (T) is off about 0.1%, and Abbvie (ABBV) is lower by about 0.8%. Among the largest underlying components of AMCA, in morning trading today AT&T (T) is down about 0.1%, and UnitedHealth Group (UNH) is lower by about 0.6%. VIDEO: SDY, AMCA: Big... | Among the largest underlying components of SDY, in morning trading today AT&T (T) is off about 0.1%, and Abbvie (ABBV) is lower by about 0.8%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the SPDR S&P Dividend ETF (SDY), where 13,... | Among the largest underlying components of SDY, in morning trading today AT&T (T) is off about 0.1%, and Abbvie (ABBV) is lower by about 0.8%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the SPDR S&P Dividend ETF (SDY), where 13,... |
24,909 | 2019-08-12 00:00:00 UTC | 10 Medical Marijuana Stocks to Cure Your Portfolio | ABBV | https://www.nasdaq.com/articles/10-medical-marijuana-stocks-to-cure-your-portfolio-2019-08-12 | null | null | Editor’s note: This story was previously published in April 2019. It has since been updated and republished.
Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, toward legalization shifted dramatically from strongly opposed to mostly supportive. Thi... | Here are 10 names to consider: AbbVie (ABBV) Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Source: Shutterstock Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Source: Shutterstock Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Source: Shutterstock Still, AbbVie maintains some botani... | Here are 10 names to consider: AbbVie (ABBV) Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Source: Shutterstock Still, AbbVie maintains some botani... |
24,910 | 2019-08-11 00:00:00 UTC | 3 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2019-08-11 | null | null | What's better than a stock that pays you to own it? How about a stock that pays you to own it and is also really cheap?
Many investors, especially retirees, love dividend stocks because they pay out dividends on a regular basis. Some dividend stocks can be quite pricey because investors like them so much. But not all o... | Three dividend stocks appear to be embarrassingly cheap right now: AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Gilead Sciences (NASDAQ: GILD). AbbVie AbbVie pays a mouthwatering dividend yield of nearly 6.6%. Is there a catch with AbbVie? | Three dividend stocks appear to be embarrassingly cheap right now: AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Gilead Sciences (NASDAQ: GILD). Two downsides to these bargain dividend stocks AbbVie, CVS Health, and Gilead offer high dividend yields and are inexpensive relative to most stocks on the market. AbbVie A... | Three dividend stocks appear to be embarrassingly cheap right now: AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Gilead Sciences (NASDAQ: GILD). Two downsides to these bargain dividend stocks AbbVie, CVS Health, and Gilead offer high dividend yields and are inexpensive relative to most stocks on the market. AbbVie A... | Investors must be willing to accept those trade-offs before buying AbbVie, CVS Health, or Gilead Sciences. Three dividend stocks appear to be embarrassingly cheap right now: AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Gilead Sciences (NASDAQ: GILD). AbbVie AbbVie pays a mouthwatering dividend yield of nearly 6.6%. |
24,911 | 2019-08-11 00:00:00 UTC | 3 Top Stocks With High Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-top-stocks-with-high-dividend-yields-2019-08-11 | null | null | For dividend stocks, yield is king. But there are other considerations investors should be aware of before scanning the stock market for high-yielding companies. Quality of yield is important, for instance, but so are a company's prospects. A high yield, after all, may not mean much if the stock itself is about to tank... | They came back with Philip Morris International (NYSE: PM), BP (NYSE: BP), and AbbVie (NYSE: ABBV). This big pharma is a big bargain Keith Speights (AbbVie): You might think that a stock that pays a 6.5% dividend yield would have horrible growth prospects. But that's not the case for AbbVie. | They came back with Philip Morris International (NYSE: PM), BP (NYSE: BP), and AbbVie (NYSE: ABBV). This big pharma is a big bargain Keith Speights (AbbVie): You might think that a stock that pays a 6.5% dividend yield would have horrible growth prospects. But that's not the case for AbbVie. | This big pharma is a big bargain Keith Speights (AbbVie): You might think that a stock that pays a 6.5% dividend yield would have horrible growth prospects. They came back with Philip Morris International (NYSE: PM), BP (NYSE: BP), and AbbVie (NYSE: ABBV). But that's not the case for AbbVie. | This big pharma is a big bargain Keith Speights (AbbVie): You might think that a stock that pays a 6.5% dividend yield would have horrible growth prospects. They came back with Philip Morris International (NYSE: PM), BP (NYSE: BP), and AbbVie (NYSE: ABBV). But that's not the case for AbbVie. |
24,912 | 2019-08-06 00:00:00 UTC | Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie | ABBV | https://www.nasdaq.com/articles/allergan-boosts-2019-guidance-while-waiting-to-be-acquired-by-abbvie-2019-08-06 | null | null | It's been an eventful year for Allergan (NYSE: AGN). That's to be expected, with AbbVie announcing in June that it plans to acquire the drugmaker for $63 billion.
Allergan added another twist to its eventful 2019 when it announced its second-quarter results before the market opened on Tuesday. Here's what you need to ... | That's to be expected, with AbbVie announcing in June that it plans to acquire the drugmaker for $63 billion. And the big development for Allergan is the pending acquisition by AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. | That's to be expected, with AbbVie announcing in June that it plans to acquire the drugmaker for $63 billion. And the big development for Allergan is the pending acquisition by AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. | That's to be expected, with AbbVie announcing in June that it plans to acquire the drugmaker for $63 billion. And the big development for Allergan is the pending acquisition by AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. | That's to be expected, with AbbVie announcing in June that it plans to acquire the drugmaker for $63 billion. And the big development for Allergan is the pending acquisition by AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. |
24,913 | 2019-08-04 00:00:00 UTC | These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024 | ABBV | https://www.nasdaq.com/articles/these-5-prescription-drugs-will-generate-a-jaw-dropping-%2462.3-billion-in-2024-2019-08-04 | null | null | America has a serious drug problem. Apart from the raging opioid crisis that's forecast to claim the lives of nearly half a million people over the next decade, the country is also reeling from the exorbitant costs associated with specialty medicines. By 2024, the top five best-selling medicines are projected to genera... | AbbVie's (NYSE: ABBV) flagship anti-inflammatory medicine Humira is predicted to slip to second place on this list, with an estimated 2024 revenue forecast of $12.4 billion. AbbVie and Johnson & Johnson's (NYSE: JNJ) game-changing blood cancer drug Imbruvica is set to occupy fifth place, with an estimated revenue haul ... | AbbVie's (NYSE: ABBV) flagship anti-inflammatory medicine Humira is predicted to slip to second place on this list, with an estimated 2024 revenue forecast of $12.4 billion. AbbVie and Johnson & Johnson's (NYSE: JNJ) game-changing blood cancer drug Imbruvica is set to occupy fifth place, with an estimated revenue haul ... | AbbVie and Johnson & Johnson's (NYSE: JNJ) game-changing blood cancer drug Imbruvica is set to occupy fifth place, with an estimated revenue haul of $9.5 billion. AbbVie's (NYSE: ABBV) flagship anti-inflammatory medicine Humira is predicted to slip to second place on this list, with an estimated 2024 revenue forecast o... | AbbVie's (NYSE: ABBV) flagship anti-inflammatory medicine Humira is predicted to slip to second place on this list, with an estimated 2024 revenue forecast of $12.4 billion. AbbVie and Johnson & Johnson's (NYSE: JNJ) game-changing blood cancer drug Imbruvica is set to occupy fifth place, with an estimated revenue haul ... |
24,914 | 2019-08-02 00:00:00 UTC | iShares U.S. Healthcare ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-u.s.-healthcare-etf-experiences-big-outflow-2019-08-02 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $28.9 million dollar outflow -- that's a 1.4% decrease week over week (from 10,900,000 to 10,750,000). Among t... | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Anthem Inc (Symbol: ANTM) is lower by about 1.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Anthem Inc (Symbol: ANTM) is lower by about 1.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Anthem Inc (Symbol: ANTM) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one... | Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Anthem Inc (Symbol: ANTM) is lower by about 1.2%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performan... |
24,915 | 2019-08-01 00:00:00 UTC | Thursday 8/1 Insider Buying Report: ABBV, WTRE | ABBV | https://www.nasdaq.com/articles/thursday-8-1-insider-buying-report%3A-abbv-wtre-2019-08-01 | null | null | Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys... | VIDEO: Thursday 8/1 Insider Buying Report: ABBV, WTRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At AbbVie (ABBV), a filing with the SEC revealed that on Tuesday, Director Roxanne S. Austin bought 10,000 shares of ABBV, at a cost... | VIDEO: Thursday 8/1 Insider Buying Report: ABBV, WTRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At AbbVie (ABBV), a filing with the SEC revealed that on Tuesday, Director Roxanne S. Austin bought 10,000 shares of ABBV, at a cost... | At AbbVie (ABBV), a filing with the SEC revealed that on Tuesday, Director Roxanne S. Austin bought 10,000 shares of ABBV, at a cost of $66.35 each, for a total investment of $663,500. AbbVie is trading up about 0.1% on the day Thursday. VIDEO: Thursday 8/1 Insider Buying Report: ABBV, WTRE The views and opinions expre... | At AbbVie (ABBV), a filing with the SEC revealed that on Tuesday, Director Roxanne S. Austin bought 10,000 shares of ABBV, at a cost of $66.35 each, for a total investment of $663,500. AbbVie is trading up about 0.1% on the day Thursday. VIDEO: Thursday 8/1 Insider Buying Report: ABBV, WTRE The views and opinions expre... |
24,916 | 2019-07-30 00:00:00 UTC | Why Neurocrine Biosciences Stock Is Jumping Today | ABBV | https://www.nasdaq.com/articles/why-neurocrine-biosciences-stock-is-jumping-today-2019-07-30 | null | null | What happened
Shares of Neurocrine Biosciences (NASDAQ: NBIX) were trading almost 10% higher as of 12:20 p.m. EDT Tuesday after the biotech company announced better-than-expected second-quarter results after the market closed on Monday.
So what
One good quarter (or one bad quarter, for that matter) doesn't really mean... | AbbVie plans to file this year for FDA approval of elagolix, a drug developed by Neurocrine, as a treatment for uterine fibroids. Elagolix is already approved to manage endometriosis pain, and is marketed by AbbVie under the brand name Orilissa. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights... | AbbVie plans to file this year for FDA approval of elagolix, a drug developed by Neurocrine, as a treatment for uterine fibroids. Elagolix is already approved to manage endometriosis pain, and is marketed by AbbVie under the brand name Orilissa. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights... | AbbVie plans to file this year for FDA approval of elagolix, a drug developed by Neurocrine, as a treatment for uterine fibroids. Elagolix is already approved to manage endometriosis pain, and is marketed by AbbVie under the brand name Orilissa. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights... | AbbVie plans to file this year for FDA approval of elagolix, a drug developed by Neurocrine, as a treatment for uterine fibroids. Elagolix is already approved to manage endometriosis pain, and is marketed by AbbVie under the brand name Orilissa. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights... |
24,917 | 2019-07-30 00:00:00 UTC | Neurocrine Biosciences Posts Sizzling Sales Growth in Q2 | ABBV | https://www.nasdaq.com/articles/neurocrine-biosciences-posts-sizzling-sales-growth-in-q2-2019-07-30 | null | null | Neurocrine Biosciences (NASDAQ: NBIX) shareholders should be pleased with the stock so far in 2019. The biotech's share price is up more than 30% year to date. And it reported solid revenue growth in its first-quarter results announced in April.
Anyone wondering if Neurocrine could keep the momentum going got a strong... | Its partner AbbVie should file for FDA approval of elagolix in treating uterine fibroids later this year. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. Anyone wondering if Neurocrine could keep the momentum going got a strong affirmative when the company announced its... | Its partner AbbVie should file for FDA approval of elagolix in treating uterine fibroids later this year. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. And it reported solid revenue growth in its first-quarter results announced in April. | Its partner AbbVie should file for FDA approval of elagolix in treating uterine fibroids later this year. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. Revenue jumped nearly 90% year over year to $183.6 million. | Its partner AbbVie should file for FDA approval of elagolix in treating uterine fibroids later this year. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. Revenue jumped nearly 90% year over year to $183.6 million. |
24,918 | 2019-07-29 00:00:00 UTC | Biotech Stocks Facing FDA Decision In August 2019 | ABBV | https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-august-2019-2019-07-29 | null | null | (RTTNews) - After having had a banner year for new drug approvals in 2018, hitting a record number of 59, it looks like the pace of FDA approval is slowing down this year. Only 16 new drugs have been greenlighted so far this year compared to 26 during the same period last year.
On July 24, 2019, the FDA approved the gl... | On July 24, 2019, the FDA approved the glucagon nasal powder Baqsimi from Eli Lilly (LLY) for patients with severe hypoglycemia. Some of the newsworthy stories of July on the regulatory front that merit mention are the approval of the first Lyrica generics, and the FDA taking significant action to protect women from br... | Some of the newsworthy stories of July on the regulatory front that merit mention are the approval of the first Lyrica generics, and the FDA taking significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). On July 24, 2019, the FDA requested Allergan to recall specifi... | (RTTNews) - After having had a banner year for new drug approvals in 2018, hitting a record number of 59, it looks like the pace of FDA approval is slowing down this year. Some of the newsworthy stories of July on the regulatory front that merit mention are the approval of the first Lyrica generics, and the FDA taking ... | (RTTNews) - After having had a banner year for new drug approvals in 2018, hitting a record number of 59, it looks like the pace of FDA approval is slowing down this year. Some of the newsworthy stories of July on the regulatory front that merit mention are the approval of the first Lyrica generics, and the FDA taking ... |
24,919 | 2019-07-29 00:00:00 UTC | Noteworthy Monday Option Activity: SYNA, ABBV, VGR | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-syna-abbv-vgr-2019-07-29 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Synaptics Inc (Symbol: SYNA), where a total of 2,466 contracts have traded so far, representing approximately 246,600 underlying shares. That amounts to about 47.1% of SYNA's average daily trading volume over th... | Especially high volume was seen for the $70 strike call option expiring September 20, 2019, with 15,274 contracts trading so far today, representing approximately 1.5 million underlying shares of ABBV. Below is a chart showing SYNA's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbV... | Below is a chart showing SYNA's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 55,778 contracts, representing approximately 5.6 million underlying shares or approximately 47% of ABBV's average daily trading volume over the past m... | Below is a chart showing SYNA's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 55,778 contracts, representing approximately 5.6 million underlying shares or approximately 47% of ABBV's average daily trading volume over the past m... | Below is a chart showing SYNA's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 55,778 contracts, representing approximately 5.6 million underlying shares or approximately 47% of ABBV's average daily trading volume over the past m... |
24,920 | 2019-07-26 00:00:00 UTC | AbbVie Boosts FY19 Adj. EPS Outlook - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-boosts-fy19-adj.-eps-outlook-quick-facts-2019-07-26 | null | null | (RTTNews) - While reporting financial results for the second quarter, biopharmaceutical company AbbVie Inc. (ABBV) on Friday raised its adjusted earnings guidance for the full-year 2019.
For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.82 to $8.92 per share, up from the prior guidance range of $8... | (RTTNews) - While reporting financial results for the second quarter, biopharmaceutical company AbbVie Inc. (ABBV) on Friday raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.82 to $8.92 per share, up from the prior guidance range of $8... | (RTTNews) - While reporting financial results for the second quarter, biopharmaceutical company AbbVie Inc. (ABBV) on Friday raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.82 to $8.92 per share, up from the prior guidance range of $8... | (RTTNews) - While reporting financial results for the second quarter, biopharmaceutical company AbbVie Inc. (ABBV) on Friday raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.82 to $8.92 per share, up from the prior guidance range of $8... | (RTTNews) - While reporting financial results for the second quarter, biopharmaceutical company AbbVie Inc. (ABBV) on Friday raised its adjusted earnings guidance for the full-year 2019. For fiscal 2019, AbbVie now projects adjusted earnings in a range of $8.82 to $8.92 per share, up from the prior guidance range of $8... |
24,921 | 2019-07-26 00:00:00 UTC | Bristol-Myers Gets Positive CHMP Opinion For Empliciti | ABBV | https://www.nasdaq.com/articles/bristol-myers-gets-positive-chmp-opinion-for-empliciti-2019-07-26 | null | null | (RTTNews) - Bristol-Myers Squibb Co. (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti or elotuzumab plus pomalidomide and low-dose dexamethasone for the treatment of adult patients ... | Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. (RTTNews) - Bristol-Myers Squibb Co. (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion on a Type-I... | Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. (RTTNews) - Bristol-Myers Squibb Co. (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion on a Type-I... | Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. (RTTNews) - Bristol-Myers Squibb Co. (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion on a Type-I... | Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. (RTTNews) - Bristol-Myers Squibb Co. (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion on a Type-I... |
24,922 | 2019-07-26 00:00:00 UTC | 5 Things You Need to Know From AbbVie's Q2 Earnings Results | ABBV | https://www.nasdaq.com/articles/5-things-you-need-to-know-from-abbvies-q2-earnings-results-2019-07-26 | null | null | AbbVie (NYSE: ABBV) needed some good news: Its announcement late last month of a plan to acquire Allergan went over like a lead balloon on Wall Street, and its stock price is down 25% so far this year. Investors continue to worry about the slumping sales of the big pharma company's top-selling drug Humira.
However, the... | AbbVie (NYSE: ABBV) needed some good news: Its announcement late last month of a plan to acquire Allergan went over like a lead balloon on Wall Street, and its stock price is down 25% so far this year. CEO Rick Gonzalez talked up the deal, calling it "a transformative transaction that will provide scale and diversity t... | In Q2, combined sales for AbbVie's HCV drugs Mavyret and Viekira fell 19.4% year over year to $784 million. Management is guiding for higher adjusted earnings AbbVie's most encouraging news was that it was raising its full-year 2019 adjusted earnings per share (EPS) guidance. AbbVie (NYSE: ABBV) needed some good news: ... | Revenue was down, but not as far as expected AbbVie's total revenue slipped 0.3% year over year to $8.255 billion. Sales of its blood cancer drugs kept growing In its first-quarter earnings results, there was one bright spot for AbbVie: The performance for its blood cancer drugs Imbruvica and Venclexta. In Q2, combined... | AbbVie (NYSE: ABBV) needed some good news: Its announcement late last month of a plan to acquire Allergan went over like a lead balloon on Wall Street, and its stock price is down 25% so far this year. Here are five things you need to know about AbbVie's Q2 earnings update. Revenue was down, but not as far as expected ... |
24,923 | 2019-07-26 00:00:00 UTC | AbbVie Earnings: ABBV Stock Pops on Q2 Beat | ABBV | https://www.nasdaq.com/articles/abbvie-earnings%3A-abbv-stock-pops-on-q2-beat-2019-07-26 | null | null | AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday.
Source: Shutterstock
AbbVie (NYSE:) reported earnings per share of $2.26 for the second quarter of the year. This is an increase over the company’s earnings per share of $2.00 from the same time last year. It was also good news for ABBV stock ... | Source: Shutterstock AbbVie (NYSE:) reported earnings per share of $2.26 for the second quarter of the year. It was also good news for ABBV stock by beating out Wall Street’s earnings per share estimate of $2.21 for the quarter. Despite this, it was still a boon to ABBV stock by coming in above analysts’ revenue estima... | It was also good news for ABBV stock by beating out Wall Street’s earnings per share estimate of $2.21 for the quarter. The AbbVie earnings report for the second quarter of the year also has operating income coming in at $3.40 billion. AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday. | Source: Shutterstock AbbVie (NYSE:) reported earnings per share of $2.26 for the second quarter of the year. It was also good news for ABBV stock by beating out Wall Street’s earnings per share estimate of $2.21 for the quarter. The AbbVie earnings report for the second quarter of the year also has operating income com... | Source: Shutterstock AbbVie (NYSE:) reported earnings per share of $2.26 for the second quarter of the year. The AbbVie earnings report for the second quarter of the year also has operating income coming in at $3.40 billion. AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday. |
24,924 | 2019-07-24 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-in-july-2019-07-24 | null | null | The demand for high-quality healthcare remains strong in good times and in bad. That makes the sector a great place for investors to search for stock ideas.
Which stocks do we favor for the long term? We asked a team of Motley Fool contributors to weigh in, and they picked AbbVie (NYSE: ABBV), Intercept Pharmaceuticals... | Those cost savings are expected to help the company protect its ability to pay and grow its dividends, which is important to many investors attracted to AbbVie's nearly 6% yield. We asked a team of Motley Fool contributors to weigh in, and they picked AbbVie (NYSE: ABBV), Intercept Pharmaceuticals (NASDAQ: ICPT), and I... | A merger that makes things less ugly Chuck Saletta (AbbVie): Healthcare titan AbbVie has a major problem. We asked a team of Motley Fool contributors to weigh in, and they picked AbbVie (NYSE: ABBV), Intercept Pharmaceuticals (NASDAQ: ICPT), and Inogen (NASDAQ: INGN). AbbVie's low market price compared to its forward e... | In a nutshell, the merger buys AbbVie time -- time to better prepare for the loss of Humira, time to attempt to find more blockbusters to potentially replace that lost revenue, and time to try and squeeze more efficiencies to deliver more value. We asked a team of Motley Fool contributors to weigh in, and they picked A... | That new lease on life makes now a reasonable time to consider an investment in AbbVie. We asked a team of Motley Fool contributors to weigh in, and they picked AbbVie (NYSE: ABBV), Intercept Pharmaceuticals (NASDAQ: ICPT), and Inogen (NASDAQ: INGN). A merger that makes things less ugly Chuck Saletta (AbbVie): Healthca... |
24,925 | 2019-07-23 00:00:00 UTC | How to Invest in Cancer-Fighting Stocks | ABBV | https://www.nasdaq.com/articles/how-to-invest-in-cancer-fighting-stocks-2019-07-23 | null | null | A 19th-century surgeon described cancer as "the emperor of all maladies, the king of terrors." Cancer isn't just one disease. Instead, it includes a wide range of diseases in which abnormal cells in the body divide uncontrollably.
But the reign of this terrible "emperor" is definitely under attack. Over the last severa... | AbbVie AbbVie is best known for immunology drug Humira, which currently reigns as the world's top-selling drug. In addition to Imbruvica, AbbVie's lineup includes another fast-rising cancer star with Venclexta. The challenge for AbbVie will be to offset declining sales for Humira, which currently generates more than 56... | AbbVie AbbVie is best known for immunology drug Humira, which currently reigns as the world's top-selling drug. In addition to Imbruvica, AbbVie's lineup includes another fast-rising cancer star with Venclexta. The challenge for AbbVie will be to offset declining sales for Humira, which currently generates more than 56... | AbbVie AbbVie is best known for immunology drug Humira, which currently reigns as the world's top-selling drug. In addition to Imbruvica, AbbVie's lineup includes another fast-rising cancer star with Venclexta. The challenge for AbbVie will be to offset declining sales for Humira, which currently generates more than 56... | AbbVie AbbVie is best known for immunology drug Humira, which currently reigns as the world's top-selling drug. In addition to Imbruvica, AbbVie's lineup includes another fast-rising cancer star with Venclexta. The challenge for AbbVie will be to offset declining sales for Humira, which currently generates more than 56... |
24,926 | 2019-07-23 00:00:00 UTC | Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings | ABBV | https://www.nasdaq.com/articles/why-bristol-myers-squibb-stock-is-stumbling-ahead-of-earnings-2019-07-23 | null | null | Ahead of its quarterly earnings report scheduled for July 25, Bristol-Myers Squibb (NYSE:) found itself trading at fresh 52-week lows. While BMY stock has kept up with the iShares Nasdaq Biotechnology ETF (NASDAQ:) in that time, investors are getting increasingly negative on the company. With that in mind, what should ... | AbbVie (NYSE:) has the same strategy with its Allergan (NYSE:) buyout. As of this writing, Chris Lau owned shares in ABBV. Ahead of its quarterly earnings report scheduled for July 25, Bristol-Myers Squibb (NYSE:) found itself trading at fresh 52-week lows. | AbbVie (NYSE:) has the same strategy with its Allergan (NYSE:) buyout. As of this writing, Chris Lau owned shares in ABBV. Strong Fundamentals Bristol Myers shares may bring pain for investors, but the company is a fundamentally strong company with a top-notch management team. | AbbVie (NYSE:) has the same strategy with its Allergan (NYSE:) buyout. As of this writing, Chris Lau owned shares in ABBV. While BMY stock has kept up with the iShares Nasdaq Biotechnology ETF (NASDAQ:) in that time, investors are getting increasingly negative on the company. | AbbVie (NYSE:) has the same strategy with its Allergan (NYSE:) buyout. As of this writing, Chris Lau owned shares in ABBV. Ahead of its quarterly earnings report scheduled for July 25, Bristol-Myers Squibb (NYSE:) found itself trading at fresh 52-week lows. |
24,927 | 2019-07-21 00:00:00 UTC | AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout | ABBV | https://www.nasdaq.com/articles/abbvies-acquisitions-report-card-shows-investors-have-a-reason-to-worry-about-the-allergan | null | null | You can't predict the future by merely looking at the past. But the past does give clues that help us make educated guesses about what the future might hold.
AbbVie (NYSE: ABBV) announced in June that it plans to acquire Allergan (NYSE: AGN). Many immediately panned the deal as a $63 billion mistake. Others were more o... | Could the company's previous deals provide some insight into how adept AbbVie's team has been at identifying the real value of potential acquisition targets? Here's AbbVie's acquisitions report card: Data sources: Company news releases, author's estimations of grades. AbbVie (NYSE: ABBV) announced in June that it plans... | Here's AbbVie's acquisitions report card: Data sources: Company news releases, author's estimations of grades. AbbVie (NYSE: ABBV) announced in June that it plans to acquire Allergan (NYSE: AGN). This isn't the first acquisition for AbbVie. | If we included this deal in AbbVie's report card, I think the company would have another grade of D. My grading rationale Let's look at why I assigned those grades to each of AbbVie's acquisitions. I almost gave the company an "incomplete" grade on this deal, but I think AbbVie really deserves a D. Pharmacyclics: AbbVi... | This isn't the first acquisition for AbbVie. This acquisition is at best a D for AbbVie. AbbVie (NYSE: ABBV) announced in June that it plans to acquire Allergan (NYSE: AGN). |
24,928 | 2019-07-21 00:00:00 UTC | Better Buy: Pfizer vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy%3A-pfizer-vs.-abbvie-2019-07-21 | null | null | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have a lot in common. Both big drugmakers are about to experience the impact of a major blockbuster losing market share. Both have promising new drugs and pipelines. Both have rewarded shareholders with great dividends. And both companies have announced acquisitions of Allerga... | Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have a lot in common. There's also another common denominator for Pfizer and AbbVie: Both stocks are underperforming the broader market so far this year. The case for AbbVie AbbVie's big headwind is the onslaught of biosimilar competition in Europe for its top-selling drug, Hu... | With its mouthwatering dividend yield, AbbVie stock doesn't have to rise much to deliver strong total returns. Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have a lot in common. There's also another common denominator for Pfizer and AbbVie: Both stocks are underperforming the broader market so far this year. | The case for AbbVie AbbVie's big headwind is the onslaught of biosimilar competition in Europe for its top-selling drug, Humira. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie and Pfizer. Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have a lot in common. | With its mouthwatering dividend yield, AbbVie stock doesn't have to rise much to deliver strong total returns. Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have a lot in common. There's also another common denominator for Pfizer and AbbVie: Both stocks are underperforming the broader market so far this year. |
24,929 | 2019-07-20 00:00:00 UTC | 8 More Big Pharma Events in 2019 You Don't Want to Miss | ABBV | https://www.nasdaq.com/articles/8-more-big-pharma-events-in-2019-you-dont-want-to-miss-2019-07-20 | null | null | It's going to be an action-packed second half for a handful of big pharmaceutical companies, and perhaps the most interesting six-month stretch in Novartis' (NYSE: NVS) history. Recently launched therapies from the Swiss pharma giant and Pfizer (NYSE: PFE) will be closely watched for different reasons.
AbbVie (NYSE: AB... | AbbVie (NYSE: ABBV) and Novartis are expecting important decisions from the Food and Drug Administration (FDA), and clinical trial readouts from Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) could help their cancer immunotherapy stars shine even brighter. Big decisions Annual sales of AbbVie's flagship rheumat... | AbbVie (NYSE: ABBV) and Novartis are expecting important decisions from the Food and Drug Administration (FDA), and clinical trial readouts from Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) could help their cancer immunotherapy stars shine even brighter. Big decisions Annual sales of AbbVie's flagship rheumat... | AbbVie (NYSE: ABBV) and Novartis are expecting important decisions from the Food and Drug Administration (FDA), and clinical trial readouts from Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) could help their cancer immunotherapy stars shine even brighter. Big decisions Annual sales of AbbVie's flagship rheumat... | AbbVie (NYSE: ABBV) and Novartis are expecting important decisions from the Food and Drug Administration (FDA), and clinical trial readouts from Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) could help their cancer immunotherapy stars shine even brighter. Big decisions Annual sales of AbbVie's flagship rheumat... |
24,930 | 2019-07-19 00:00:00 UTC | IYH, ABBV, CI, BDX: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iyh-abbv-ci-bdx%3A-large-outflows-detected-at-etf-2019-07-19 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $29.3 million dollar outflow -- that's a 1.4% decrease week over week (from 11,100,000 to 10,950,000). Among t... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Cigna Corp (Symbol: CI) is off about 1.1%, and Becton, Dickinson & Co (Symbol: BDX) is lower by about 0.3%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Cigna Corp (Symbol: CI) is off about 1.1%, and Becton, Dickinson & Co (Symbol: BDX) is lower by about 0.3%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Cigna Corp (Symbol: CI) is off about 1.1%, and Becton, Dickinson & Co (Symbol: BDX) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Cigna Corp (Symbol: CI) is off about 1.1%, and Becton, Dickinson & Co (Symbol: BDX) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
24,931 | 2019-07-19 00:00:00 UTC | Investing in Chicago Stocks | ABBV | https://www.nasdaq.com/articles/investing-in-chicago-stocks-2019-07-19 | null | null | From its earliest days of incorporation back in the late 1830s, Chicago has been all about trade. The city cultivated that early trade focus and used it to become one of the most diverse business climates in the United States. If you're considering investing in Chicago stocks -- the publicly traded stocks of the busine... | It could be the patents they hold (AbbVie, Motorola Solutions), the high cost of switching to a competitor (Northern Trust), complicated regulations that limit access to the market (Boeing, Exelon), or cost efficiencies (Allstate) that these companies know how to take advantage of. Boeing stock is down over serious iss... | It could be the patents they hold (AbbVie, Motorola Solutions), the high cost of switching to a competitor (Northern Trust), complicated regulations that limit access to the market (Boeing, Exelon), or cost efficiencies (Allstate) that these companies know how to take advantage of. Boeing stock is down over serious iss... | Boeing stock is down over serious issues with its 737 MAX plane; Kraft Heinz stock is down on issues including a writedown, an SEC probe and a slashed dividend; McDonald's stock is up in recent years because of some smart changes in strategy; AbbVie stock is down because it just offered to buy Allergan in a $63 billion... | What companies might come to Chicago? It could be the patents they hold (AbbVie, Motorola Solutions), the high cost of switching to a competitor (Northern Trust), complicated regulations that limit access to the market (Boeing, Exelon), or cost efficiencies (Allstate) that these companies know how to take advantage of.... |
24,932 | 2019-07-18 00:00:00 UTC | 3 Top Dividend Stocks With Yields Over 4% | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-with-yields-over-4-2019-07-18 | null | null | Even with an improving economy, many are sounding the alarm that a downturn may be coming, leading the Federal Reserve to take the position there will be no rate hikes in the immediate future. Dicey economic times make an income-producing portfolio a solid choice because, over extended periods, stocks that pay dividend... | All told, AbbVie's enormous dividend yield and rock-bottom valuation should appeal to most income investors, but shareholders will definitely want to keep a close eye on its underlying fundamentals in the years to come. Stocks with above-average yields are good candidates for achieving the best performance, and three M... | A Dividend Aristocrat with an unusually high yield George Budwell (AbbVie): Dividend Aristocrats rarely sport yields on par with junk bonds, but AbbVie isn't your prototypical blue chip income stock. Stocks with above-average yields are good candidates for achieving the best performance, and three Motley Fool contribut... | Stocks with above-average yields are good candidates for achieving the best performance, and three Motley Fool contributors have picked AT&T (NYSE: T), AbbVie (NYSE: ABBV), and Harley-Davidson (NYSE: HOG) as stocks with dividends above 4% that could pay off in the long term. A Dividend Aristocrat with an unusually high... | A Dividend Aristocrat with an unusually high yield George Budwell (AbbVie): Dividend Aristocrats rarely sport yields on par with junk bonds, but AbbVie isn't your prototypical blue chip income stock. Stocks with above-average yields are good candidates for achieving the best performance, and three Motley Fool contribut... |
24,933 | 2019-07-16 00:00:00 UTC | Commit To Purchase AbbVie At $40, Earn 3.2% Using Options | ABBV | https://www.nasdaq.com/articles/commit-to-purchase-abbvie-at-%2440-earn-3.2-using-options-2019-07-16 | null | null | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but tentative about paying the going market price of $69.59/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2021 put at the $40 strike, which ... | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but tentative about paying the going market price of $69.59/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highli... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $40 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the Janu... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $40 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the Janu... | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but tentative about paying the going market price of $69.59/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highli... |
24,934 | 2019-07-13 00:00:00 UTC | Better Buy: AbbVie vs. Merck | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-merck-2019-07-13 | null | null | Big pharma stocks AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) are on very different paths right now. With its top-selling drug Humira under pressure from biosimilars, AbbVie has struggled mightily. Meanwhile, Merck's shares continue to rise, fueled largely by rising sales for its blockbuster cancer immunotherapy Keytruda... | The acquisition boosts AbbVie's revenue and earnings growth prospects, even with some uncertainty for some of Allergan's top products. With its fantastic dividend yield, AbbVie doesn't have to deliver much in the way of earnings growth to allow the stock's total return to reach double-digit percentages. Big pharma stoc... | Big pharma stocks AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) are on very different paths right now. Despite the long-anticipated sales decline for Humira, AbbVie will almost certainly deliver overall revenue and earnings growth over the next several years. With its top-selling drug Humira under pressure from biosimilars... | Big pharma stocks AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) are on very different paths right now. AbbVie's shares trade at just over 7.5 times expected earnings, making AbbVie one of the cheapest big pharma stocks on the market. With its fantastic dividend yield, AbbVie doesn't have to deliver much in the way of earni... | Sure, many investors view this deal as a big mistake for AbbVie. But buying Allergan definitely will reduce AbbVie's dependence on Humira. Big pharma stocks AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) are on very different paths right now. |
24,935 | 2019-07-11 00:00:00 UTC | ITOT, ABBV, GE, AXP: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/itot-abbv-ge-axp%3A-large-outflows-detected-at-etf-2019-07-11 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $118.7 million dollar outflow -- that's a 0.5% decrease week over week (from 319,300,000 to ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.7%, General Electric Co (Symbol: GE) is off about 0.7%, and American Express Co. (Symbol: AXP) is lower by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.7%, General Electric Co (Symbol: GE) is off about 0.7%, and American Express Co. (Symbol: AXP) is lower by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.7%, General Electric Co (Symbol: GE) is off about 0.7%, and American Express Co. (Symbol: AXP) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.7%, General Electric Co (Symbol: GE) is off about 0.7%, and American Express Co. (Symbol: AXP) is lower by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one ... |
24,936 | 2019-07-10 00:00:00 UTC | Ex-Dividend Reminder: Becton, Dickinson, Abbott Laboratories and AbbVie | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-becton-dickinson-abbott-laboratories-and-abbvie-2019-07-10 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 8/1... | If they do continue, the current estimated yields on annualized basis would be 4.92% for Becton, Dickinson & Co, 1.49% for Abbott Laboratories, and 5.98% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), ... | Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 8/1... | Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 8/1... | If they do continue, the current estimated yields on annualized basis would be 4.92% for Becton, Dickinson & Co, 1.49% for Abbott Laboratories, and 5.98% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), ... |
24,937 | 2019-07-09 00:00:00 UTC | The S&P 500’s 5 Best Highest-Yielding Dividend Stocks | ABBV | https://www.nasdaq.com/articles/the-sp-500s-5-best-highest-yielding-dividend-stocks-2019-07-09 | null | null | There’s nothing more satisfying that getting money for doing nothing. That’s why dividend stocks hold so much appeal for portfolios. After a one-time investment, top dividend stocks will pay you year in and year out, for doing nothing except holding them. This has to be one of the greatest forces in all of investing. A... | AbbVie (ABBV) Dividend Yield: 5.71% Source: Shutterstock The giant pharmaceutical firms have long been great dividend stocks. This includes biotech king AbbVie (NASDAQ:). The drug has continued to drive ABBV’s dividend — currently at almost 6%. | AbbVie (ABBV) Dividend Yield: 5.71% Source: Shutterstock The giant pharmaceutical firms have long been great dividend stocks. This includes biotech king AbbVie (NASDAQ:). The drug has continued to drive ABBV’s dividend — currently at almost 6%. | AbbVie (ABBV) Dividend Yield: 5.71% Source: Shutterstock The giant pharmaceutical firms have long been great dividend stocks. This includes biotech king AbbVie (NASDAQ:). The drug has continued to drive ABBV’s dividend — currently at almost 6%. | AbbVie (ABBV) Dividend Yield: 5.71% Source: Shutterstock The giant pharmaceutical firms have long been great dividend stocks. This includes biotech king AbbVie (NASDAQ:). The drug has continued to drive ABBV’s dividend — currently at almost 6%. |
24,938 | 2019-07-04 00:00:00 UTC | Why AbbVie's Stock Sank in the First Half of 2019 | ABBV | https://www.nasdaq.com/articles/why-abbvies-stock-sank-in-the-first-half-of-2019-2019-07-04 | null | null | What happened
Biopharma giant AbbVie (NYSE: ABBV) has had an absolutely regrettable year. Through the course of the first six months of the year, the drugmaker's shares have lost a breathtaking 21.2% of their value, according to data from S&P Global Market Intelligence.
Why did investors give AbbVie's stock the cold sh... | Second, AbbVie decided to address Humira's patent cliff by acquiring Botox maker Allergan (NYSE: AGN) for a whopping $63 billion. While Skyrizi won't be a panacea for AbbVie's patent woes, it should at least help to blunt the impact of Humira's ongoing battle with biosimilars. What happened Biopharma giant AbbVie (NYSE... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! What happened Biopharma giant AbbVie (NYSE: ABBV) has had an absolutely regrettable year. Why did investors give AbbVie's stock the cold shoulder in the first half of 2019? | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! What happened Biopharma giant AbbVie (NYSE: ABBV) has had an... | AbbVie, in turn, might turn out to be an outstanding bargain if management can somehow mesh together two drastically different product portfolios while also maintaining the company's status as a Dividend Aristocrat in the years to come. * David and Tom just revealed what they believe are the ten best stocks for investo... |
24,939 | 2019-07-04 00:00:00 UTC | Why Amicus Therapeutics' Stock Perked Up in June | ABBV | https://www.nasdaq.com/articles/why-amicus-therapeutics-stock-perked-up-in-june-2019-07-04 | null | null | What happened
Shares of rare disease specialist Amicus Therapeutics (NASDAQ: FOLD) gained a healthy 10.7% in June, according to data from S&P Global Market Intelligence. What sparked this upswing?
Amicus' stock appears to have been the beneficiary of a rising-tide phenomenon last month. While the prior few months have ... | So far this year, we've seen numerous mergers and acquisitions such as Biogen's deal to acquire gene therapy specialist Nightstar Therapeutics, Bristol-Myers Squibb's megamerger with Celgene, Pfizer's acquisition of Array BioPharma, and most recently, AbbVie's $63 billion deal to tie the knot with Allergan. What happen... | So far this year, we've seen numerous mergers and acquisitions such as Biogen's deal to acquire gene therapy specialist Nightstar Therapeutics, Bristol-Myers Squibb's megamerger with Celgene, Pfizer's acquisition of Array BioPharma, and most recently, AbbVie's $63 billion deal to tie the knot with Allergan. What happen... | So far this year, we've seen numerous mergers and acquisitions such as Biogen's deal to acquire gene therapy specialist Nightstar Therapeutics, Bristol-Myers Squibb's megamerger with Celgene, Pfizer's acquisition of Array BioPharma, and most recently, AbbVie's $63 billion deal to tie the knot with Allergan. 10 stocks w... | So far this year, we've seen numerous mergers and acquisitions such as Biogen's deal to acquire gene therapy specialist Nightstar Therapeutics, Bristol-Myers Squibb's megamerger with Celgene, Pfizer's acquisition of Array BioPharma, and most recently, AbbVie's $63 billion deal to tie the knot with Allergan. While the p... |
24,940 | 2019-07-04 00:00:00 UTC | 3 Dividend Stocks That Pay You More Than Exxon Does | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-pay-you-more-than-exxon-does-2019-07-04 | null | null | Payday is awesome, but a payday you didn't have to work for is even better. Yielding a sweet 4.6% a year, ExxonMobil (NYSE: XOM) is a great way to get paid for owning a slice of the oil giant. Whether the stock is for generating income or offsetting stock market volatility, Exxon is a top pick.
But it's not the only on... | Three of our Foolish contributors think that Seagate Technology (NASDAQ: STX), AbbVie (NYSE: ABBV), and Ford (NYSE: F) are good dividend picks, too -- and all of them yield even more than Exxon does at current share prices. A beaten-up bargain dividend stock Todd Campbell (AbbVie): A high dividend yield can occur when ... | Three of our Foolish contributors think that Seagate Technology (NASDAQ: STX), AbbVie (NYSE: ABBV), and Ford (NYSE: F) are good dividend picks, too -- and all of them yield even more than Exxon does at current share prices. A beaten-up bargain dividend stock Todd Campbell (AbbVie): A high dividend yield can occur when ... | A beaten-up bargain dividend stock Todd Campbell (AbbVie): A high dividend yield can occur when a company's dividend increases faster than its stock price or when a stock price falls despite a stable dividend payout. AbbVie's only paying $120 per share in cash (the rest is being paid in the form of AbbVie stock), and A... | A beaten-up bargain dividend stock Todd Campbell (AbbVie): A high dividend yield can occur when a company's dividend increases faster than its stock price or when a stock price falls despite a stable dividend payout. AbbVie's only paying $120 per share in cash (the rest is being paid in the form of AbbVie stock), and A... |
24,941 | 2019-07-03 00:00:00 UTC | Two Dividend Payers That Beat the S&P 500 | ABBV | https://www.nasdaq.com/articles/two-dividend-payers-that-beat-the-sp-500-2019-07-03 | null | null | The Kiplinger Dividend 15, our favorite stocks for dividend income, have been riding the bull since we last checked on them in the April issue of Kiplinger's. Since then, the average stock among our dividend champs has returned 6.6%, including dividends. Standard & Poor's 500-stock index, by comparison, has gained 4.8%... | AbbVie's (ABBV, $74) shares fell 16.2% over the past 12 months, pushing the yield to 5.4%, due to fears that sales of Humira, its flagship drug, could slow. The biggest winner in the past four months: Blackstone (symbol BX, $47) , which offers investments in private equity, real estate and other alternatives. As with B... | AbbVie's (ABBV, $74) shares fell 16.2% over the past 12 months, pushing the yield to 5.4%, due to fears that sales of Humira, its flagship drug, could slow. Since then, the average stock among our dividend champs has returned 6.6%, including dividends. See Also: How Dividend Stocks Help Boost Retirement Income More imp... | AbbVie's (ABBV, $74) shares fell 16.2% over the past 12 months, pushing the yield to 5.4%, due to fears that sales of Humira, its flagship drug, could slow. Since then, the average stock among our dividend champs has returned 6.6%, including dividends. See Also: How Dividend Stocks Help Boost Retirement Income More imp... | AbbVie's (ABBV, $74) shares fell 16.2% over the past 12 months, pushing the yield to 5.4%, due to fears that sales of Humira, its flagship drug, could slow. The stock has gained 33.6% since then and 39.1% over the past 12 months. Even so, 3M has paid dividends for more than 100 years and has raised its dividend annuall... |
24,942 | 2019-07-02 00:00:00 UTC | Is AbbVie a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-buy-2019-07-02 | null | null | Ever since Abbott Laboratories spun off AbbVie (NYSE: ABBV) as a stand-alone entity approximately six years ago, the biotech has generated industry-leading levels of earnings, revenue, and dividend growth. In response, AbbVie's shares have also produced market-beating returns for its early shareholders.
However, AbbVie... | A disappointing clinical readout for its experimental cancer therapy dubbed "ROVA-T" sent shock waves through the investing community, causing AbbVie's shares to lose around a quarter of their value in the past 16 months. The big deal is that AbbVie paid a noteworthy $5.8 billion to acquire ROVA-T and this particular c... | However, AbbVie's status as biotech's top large-cap growth stock -- and one of the best dividend growth plays in all of healthcare -- abruptly ended in early 2018. While AbbVie reportedly plans to reduce its debt load by $15 billion to $18 billion by 2021, the company won't have much room to maneuver in terms of busine... | However, AbbVie's status as biotech's top large-cap growth stock -- and one of the best dividend growth plays in all of healthcare -- abruptly ended in early 2018. The big deal is that AbbVie paid a noteworthy $5.8 billion to acquire ROVA-T and this particular cancer treatment also happened to be a key centerpiece in t... | Ever since Abbott Laboratories spun off AbbVie (NYSE: ABBV) as a stand-alone entity approximately six years ago, the biotech has generated industry-leading levels of earnings, revenue, and dividend growth. In response, AbbVie's shares have also produced market-beating returns for its early shareholders. However, AbbVie... |
24,943 | 2019-07-02 00:00:00 UTC | 3 Biotechs That Have Doubled This Year (Acquisition Next?) | ABBV | https://www.nasdaq.com/articles/3-biotechs-that-have-doubled-this-year-acquisition-next-2019-07-02 | null | null | When big pharmas go shopping, you usually won't find them sifting through the clearance racks for bargains. For the most part, the large drugmakers would rather pay extra for a proven winner than buy an on-sale biotech looking to recover.
Take Array BioPharma, which had more than doubled year to date through the middle... | In February, the company signed a collaboration deal with AbbVie (NYSE: ABBV) to develop treatments for Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. A few weeks later, the Food and Drug Administration decided to lift a hold that was preventing A... | In February, the company signed a collaboration deal with AbbVie (NYSE: ABBV) to develop treatments for Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. Adverum Biotechnologies Adverum only has one drug in clinical trials, but ADVM-022, a gene thera... | In February, the company signed a collaboration deal with AbbVie (NYSE: ABBV) to develop treatments for Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. In late April, the biotech said doctors were able to treat the second eye of patients who had pr... | In February, the company signed a collaboration deal with AbbVie (NYSE: ABBV) to develop treatments for Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. One of Motley Fool co-founder David Gardner's signs of a Rule Breakers stock is past price appre... |
24,944 | 2019-07-02 00:00:00 UTC | Insiders Buy the Holdings of DLN ETF | ABBV | https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-dln-etf-2019-07-02 | null | null | A look at the weighted underlying holdings of the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN) shows an impressive 10.5% of holdings on a weighted basis have experienced insider buying within the past six months.
AbbVie Inc (Symbol: ABBV), which makes up 1.12% of the WisdomTree U.S. LargeCap Dividend Fund (Symb... | AbbVie Inc (Symbol: ABBV), which makes up 1.12% of the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $73.... | AbbVie Inc (Symbol: ABBV), which makes up 1.12% of the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $73.... | AbbVie Inc (Symbol: ABBV), which makes up 1.12% of the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $73.... | AbbVie Inc (Symbol: ABBV), which makes up 1.12% of the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABBV: ABBV — last trade: $73.... |
24,945 | 2019-07-01 00:00:00 UTC | Notable Monday Option Activity: ABBV, TTWO, MRNS | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-abbv-ttwo-mrns-2019-07-01 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 70,194 contracts have traded so far, representing approximately 7.0 million underlying shares. That amounts to about 54.3% of ABBV's average daily trading volume over ... | Particularly high volume was seen for the $70 strike call option expiring July 19, 2019, with 4,943 contracts trading so far today, representing approximately 494,300 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... | Below is a chart showing ABBV's trailing twelve month trading history, with the $70 strike highlighted in orange: Take-Two Interactive Software, Inc. (Symbol: TTWO) options are showing a volume of 6,873 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options tradin... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 70,194 contracts have traded so far, representing approximately 7.0 million underlying shares. Particularly high volume was seen for the $70 strike call option expirin... | Below is a chart showing MRNS's trailing twelve month trading history, with the $4 strike highlighted in orange: For the various different available expirations for ABBV options, TTWO options, or MRNS options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy op... |
24,946 | 2019-07-01 00:00:00 UTC | Monday 7/1 Insider Buying Report: MDCO, ABBV | ABBV | https://www.nasdaq.com/articles/monday-7/1-insider-buying-report%3A-mdco-abbv-2019-07-01 | null | null | As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys.
At Medicines, a filing with the SEC revealed that on Friday, Director Alexander J. Denner bought 50,000 shares of MDCO, for a c... | And on Wednesday, Director Roxanne S. Austin bought $776,250 worth of AbbVie, buying 11,500 shares at a cost of $67.50 each. AbbVie is trading up about 0.7% on the day Monday. Austin was up about 9.4% on the purchase at the high point of today's trading session, with ABBV trading as high as $73.85 at last check today. | Austin was up about 9.4% on the purchase at the high point of today's trading session, with ABBV trading as high as $73.85 at last check today. VIDEO: Monday 7/1 Insider Buying Report: MDCO, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nas... | Austin was up about 9.4% on the purchase at the high point of today's trading session, with ABBV trading as high as $73.85 at last check today. VIDEO: Monday 7/1 Insider Buying Report: MDCO, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nas... | And on Wednesday, Director Roxanne S. Austin bought $776,250 worth of AbbVie, buying 11,500 shares at a cost of $67.50 each. AbbVie is trading up about 0.7% on the day Monday. Austin was up about 9.4% on the purchase at the high point of today's trading session, with ABBV trading as high as $73.85 at last check today. |
24,947 | 2019-07-01 00:00:00 UTC | Acquisition Improves the Outlook of Pfizer Stock | ABBV | https://www.nasdaq.com/articles/acquisition-improves-the-outlook-of-pfizer-stock-2019-07-01 | null | null | Pfizer (NYSE: ) stock has enjoyed an uptrend that started in late April. With an upcoming quarterly dividend of 36 cents, giving Pfizer stock a yield of 3.3%, PFE stock price may rise more in the near future.
Source: Shutterstock
Pfizer’s $11.4 billion acquisition of Array BioPharma (NASDAQ: ) could be a positive, n... | I used the word “relatively” because of AbbVie’s (NYSE: ) subsequent, monstrous, $63 billion acquisition of Allergan (NYSE: ). As of this writing, the author owns shares of AbbVie. In May, Array reported statistically significant improvements of the subjects being treated in a Phase 3 trial of its mCRC treatment. | I used the word “relatively” because of AbbVie’s (NYSE: ) subsequent, monstrous, $63 billion acquisition of Allergan (NYSE: ). As of this writing, the author owns shares of AbbVie. Pfizer’s Acquisition Array may boost Pfizer stock by providing PFE with BRAF/MEK inhibitors, a potential first-in-class therapy for patien... | I used the word “relatively” because of AbbVie’s (NYSE: ) subsequent, monstrous, $63 billion acquisition of Allergan (NYSE: ). As of this writing, the author owns shares of AbbVie. Source: Shutterstock Pfizer’s $11.4 billion acquisition of Array BioPharma (NASDAQ: ) could be a positive, near-term and long-term catalys... | I used the word “relatively” because of AbbVie’s (NYSE: ) subsequent, monstrous, $63 billion acquisition of Allergan (NYSE: ). As of this writing, the author owns shares of AbbVie. Pfizer’s Acquisition Array may boost Pfizer stock by providing PFE with BRAF/MEK inhibitors, a potential first-in-class therapy for patien... |
24,948 | 2019-06-30 00:00:00 UTC | 3 Top Biotech Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-right-now-2019-06-30 | null | null | Over the prior decade, you'd be hard-pressed to find a better performing subsector than biotechnology. A number of biotech stocks, after all, have produced life-changing returns on capital over this period. Nonetheless, the industry's best days are far from over. With a wave of groundbreaking products in the pipeline, ... | They selected Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV), and Mirati Therapeutics (NASDAQ: MRTX). A big beaten-down biotech with plenty to offer Keith Speights (AbbVie): Biotech stocks, in general, have performed pretty well so far in 2019. Not AbbVie. | A big beaten-down biotech with plenty to offer Keith Speights (AbbVie): Biotech stocks, in general, have performed pretty well so far in 2019. They selected Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV), and Mirati Therapeutics (NASDAQ: MRTX). Not AbbVie. | A big beaten-down biotech with plenty to offer Keith Speights (AbbVie): Biotech stocks, in general, have performed pretty well so far in 2019. They selected Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV), and Mirati Therapeutics (NASDAQ: MRTX). Not AbbVie. | Not AbbVie. We'll see, but the acquisition doesn't change my overall view about AbbVie. They selected Biogen (NASDAQ: BIIB), AbbVie (NYSE: ABBV), and Mirati Therapeutics (NASDAQ: MRTX). |
24,949 | 2019-06-30 00:00:00 UTC | 4 Reasons to Buy AbbVie Now That It's Acquiring Allergan | ABBV | https://www.nasdaq.com/articles/4-reasons-to-buy-abbvie-now-that-its-acquiring-allergan-2019-06-30 | null | null | What in the world was AbbVie (NYSE: ABBV) thinking? The big drugmaker stunned investors by announcing last Tuesday that it plans to acquire Allergan (NYSE: AGN) for $63 billion. Many view the deal as a huge mistake for AbbVie.
I'll admit that I was highly skeptical about the Allergan acquisition. Of all the deals that ... | More importantly, I think AbbVie is now a better stock for long-term investors to buy than it was prior to its announcement of plans to acquire Allergan. The bottom line Sure, I had hoped AbbVie would scoop up a few promising smaller biotechs in a "string-of-pearls" strategy that would cement the company's position as ... | Humira is less of a problem Investors' worries about biosimilar competition for Humira have weighed on AbbVie stock for a while. The deal boosts AbbVie's growth prospects Yes, several of Allergan's products face challenges of their own. AbbVie's dividend looks even more attractive The initial reaction to AbbVie's propo... | AbbVie's dividend looks even more attractive The initial reaction to AbbVie's proposed buyout of Allergan was harsh, with AbbVie's share price plunging 15%. AbbVie CEO Rick Gonzalez even told analysts in the conference call related to the Allergan transaction that AbbVie remains "absolutely committed" to growing its di... | Does the Allergan acquisition change AbbVie's commitment to its dividend program? Whatever you think about the merits of the Allergan acquisition, AbbVie appears to be a better stock to buy as a result of the announcement of this deal. What in the world was AbbVie (NYSE: ABBV) thinking? |
24,950 | 2019-06-28 00:00:00 UTC | 4 Lower-Risk Healthcare Picks for Long-Term Investors | ABBV | https://www.nasdaq.com/articles/4-lower-risk-healthcare-picks-for-long-term-investors-2019-06-28 | null | null | Healthcare can be a scary space if you focus on the biotech and pharma side of it. Luckily, there's plenty more to the industry. In this week's episode of Industry Focus: Healthcare, host Shannon Jones talks with senior Fool analyst Jason Moser about his Healthcare and Wealthcare basket, a diversified clump of stocks w... | Shannon and Jason explain what the massive AbbVie (NYSE: ABBV)-Allergan (NYSE: AGN) tie-up does and does not means for both businesses, why growth investors shouldn't get too excited, and what shareholders of these companies should know. It's all about this AbbVie-Allergan deal. On Monday, AbbVie announced it would be ... | Shannon and Jason explain what the massive AbbVie (NYSE: ABBV)-Allergan (NYSE: AGN) tie-up does and does not means for both businesses, why growth investors shouldn't get too excited, and what shareholders of these companies should know. It's all about this AbbVie-Allergan deal. On Monday, AbbVie announced it would be ... | Shannon and Jason explain what the massive AbbVie (NYSE: ABBV)-Allergan (NYSE: AGN) tie-up does and does not means for both businesses, why growth investors shouldn't get too excited, and what shareholders of these companies should know. It's all about this AbbVie-Allergan deal. On Monday, AbbVie announced it would be ... | Jones: Let's talk a little bit about AbbVie. Shannon and Jason explain what the massive AbbVie (NYSE: ABBV)-Allergan (NYSE: AGN) tie-up does and does not means for both businesses, why growth investors shouldn't get too excited, and what shareholders of these companies should know. It's all about this AbbVie-Allergan d... |
24,951 | 2019-06-28 00:00:00 UTC | Are AbbVie and Allergan Really Better Together? | ABBV | https://www.nasdaq.com/articles/are-abbvie-and-allergan-really-better-together-2019-06-28 | null | null | The news that AbbVie (NYSE: ABBV) had inked a $63 billion deal to buy Allergan (NYSE: AGN) was not met with applause on Wall Street Tuesday. Given that the share price of Allergan is now trading far below the bid price, there are clearly questions about whether the acquisition will go through. And the response reflecte... | And the response reflected in AbbVie's stock move makes it clear that investors think it's overpaying -- though the deal price is less than half of what Pfizer intended to pay just three years ago. The news that AbbVie (NYSE: ABBV) had inked a $63 billion deal to buy Allergan (NYSE: AGN) was not met with applause on Wa... | The news that AbbVie (NYSE: ABBV) had inked a $63 billion deal to buy Allergan (NYSE: AGN) was not met with applause on Wall Street Tuesday. And the response reflected in AbbVie's stock move makes it clear that investors think it's overpaying -- though the deal price is less than half of what Pfizer intended to pay jus... | Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Allergan, because shares of AbbVie are down about 15%, and it's not like this stock's been lighting the world on fire the last 18 months.... | Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Allergan, because shares of AbbVie are down about 15%, and it's not like this stock's been lighting the world on fire the last 18 months.... |
24,952 | 2019-06-27 00:00:00 UTC | Big Pharma Gets Bigger | ABBV | https://www.nasdaq.com/articles/big-pharma-gets-bigger-2019-06-27 | null | null | In this episode of MarketFoolery, host Chris Hill talks with senior analyst Jason Moser about some fresh business news. AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) plan to join up, but the market doesn't seem that happy for them. Warren Buffett cryptically reported that there's no tension between Berkshire Hathaway (N... | AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) plan to join up, but the market doesn't seem that happy for them. AbbVie buying Allergan. Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Al... | AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) plan to join up, but the market doesn't seem that happy for them. AbbVie buying Allergan. Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Al... | Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Allergan, because shares of AbbVie are down about 15%, and it's not like this stock's been lighting the world on fire the last 18 months.... | Clearly, based on what's happening with shares of AbbVie today, it looks like there are plenty of people who don't like this deal, or at least think that they are paying too much for Allergan, because shares of AbbVie are down about 15%, and it's not like this stock's been lighting the world on fire the last 18 months.... |
24,953 | 2019-06-26 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 6/26/2019 | ABBV | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-6/26/2019-2019-06-26 | null | null | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechno... | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metab... | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metab... | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. |
24,954 | 2019-06-26 00:00:00 UTC | Wednesday’s Vital Data: AbbVie, FedEx and Micron | ABBV | https://www.nasdaq.com/articles/wednesdays-vital-data%3A-abbvie-fedex-and-micron-2019-06-26 | null | null | U.S. stock futures are trading higher on the back of optimism surrounding a trade deal. Treasury Secretary Steven Mnuchin said the U.S. was nearing a trade deal with China and is confident talks at the G-20 summit will go well.
Against this backdrop, futures on the Dow Jones Industrial Average are up 0.28% and S&P 500 ... | Abbvie (NYSE:) shares plunged after the company announced it’s acquiring Allergan (NYSE:). Let’s take a closer look: AbbVie (ABBV) Acquisition news sent AbbVie tumbling yesterday. The deal carries a $63 billion price tag and sent ABBV stock skidding 16%. | Abbvie (NYSE:) shares plunged after the company announced it’s acquiring Allergan (NYSE:). Let’s take a closer look: AbbVie (ABBV) Acquisition news sent AbbVie tumbling yesterday. The deal carries a $63 billion price tag and sent ABBV stock skidding 16%. | Abbvie (NYSE:) shares plunged after the company announced it’s acquiring Allergan (NYSE:). Let’s take a closer look: AbbVie (ABBV) Acquisition news sent AbbVie tumbling yesterday. The deal carries a $63 billion price tag and sent ABBV stock skidding 16%. | Abbvie (NYSE:) shares plunged after the company announced it’s acquiring Allergan (NYSE:). Let’s take a closer look: AbbVie (ABBV) Acquisition news sent AbbVie tumbling yesterday. The deal carries a $63 billion price tag and sent ABBV stock skidding 16%. |
24,955 | 2019-06-26 00:00:00 UTC | Health Care Sector Update for 06/26/2019: ACST, ABBV, EYEG, NBRV, AGN, JNJ, PFE, ABT, MRK, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-06-26-2019%3A-acst-abbv-eyeg-nbrv-agn-jnj-pfe-abt-mrk-amgn | null | null | Top Health Care Stocks:
JNJ: Flat
PFE: -0.07%
ABT: +0.07
MRK: +0.13%
AMGN: +0.08%
Most health care majors were higher in Wednesday's pre-market trading.
Early movers include:
(+) Acasti Pharma (ACST), which was up more than 11% after it said it remained "on track to report topline results for our primary endpoint of lo... | (+) AbbVie (ABBV) was up 2% after saying that in connection with its proposed $63 billion merger with Allergan (AGN), it signed a $38 billion bridge loan agreement with Morgan Stanley Senior Funding and MUFG Bank. Early movers include: (+) Acasti Pharma (ACST), which was up more than 11% after it said it remained "on t... | (+) AbbVie (ABBV) was up 2% after saying that in connection with its proposed $63 billion merger with Allergan (AGN), it signed a $38 billion bridge loan agreement with Morgan Stanley Senior Funding and MUFG Bank. Top Health Care Stocks: JNJ: Flat Most health care majors were higher in Wednesday's pre-market trading. | (+) AbbVie (ABBV) was up 2% after saying that in connection with its proposed $63 billion merger with Allergan (AGN), it signed a $38 billion bridge loan agreement with Morgan Stanley Senior Funding and MUFG Bank. (-) Nabriva Therapeutics (NBRV), which was down 2% after it said Tuesday that it entered into an open mark... | (+) AbbVie (ABBV) was up 2% after saying that in connection with its proposed $63 billion merger with Allergan (AGN), it signed a $38 billion bridge loan agreement with Morgan Stanley Senior Funding and MUFG Bank. Top Health Care Stocks: JNJ: Flat Most health care majors were higher in Wednesday's pre-market trading. |
24,956 | 2019-06-26 00:00:00 UTC | 3 Big Stock Charts for Wednesday: Tyson Foods, Lennar and State Street | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-tyson-foods-lennar-and-state-street-2019-06-26 | null | null | Already struggling under the weight of recent gains, investors interpreted some comments from Federal Reserve Chairman Jerome Powell in the worst possible light on Tuesday. The S&P 500 fell 0.95%, perhaps setting a tone for a return to the mean more in tune with June’s usual tepidness.
Source:
FedEx (NYSE:) did a bunch... | AbbVie (NYSE:) logged the day’s most sizeable loss by a single name, however, losing 16% on the heels of unpopular news that it was acquiring Allergan (NYSE:) at a healthy premium. Already struggling under the weight of recent gains, investors interpreted some comments from Federal Reserve Chairman Jerome Powell in the... | AbbVie (NYSE:) logged the day’s most sizeable loss by a single name, however, losing 16% on the heels of unpopular news that it was acquiring Allergan (NYSE:) at a healthy premium. Headed into the midpoint of the trading week, however, it’s the stock charts of Lennar (NYSE:), Tyson Foods (NYSE:) and State Street (NYSE:... | AbbVie (NYSE:) logged the day’s most sizeable loss by a single name, however, losing 16% on the heels of unpopular news that it was acquiring Allergan (NYSE:) at a healthy premium. Headed into the midpoint of the trading week, however, it’s the stock charts of Lennar (NYSE:), Tyson Foods (NYSE:) and State Street (NYSE:... | AbbVie (NYSE:) logged the day’s most sizeable loss by a single name, however, losing 16% on the heels of unpopular news that it was acquiring Allergan (NYSE:) at a healthy premium. Headed into the midpoint of the trading week, however, it’s the stock charts of Lennar (NYSE:), Tyson Foods (NYSE:) and State Street (NYSE:... |
24,957 | 2019-06-25 00:00:00 UTC | What Happened in the Stock Market Today | ABBV | https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-06-25 | null | null | Major indexes slumped Tuesday after comments from Federal Reserve officials indicated that an interest rate cut may not happen soon. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) opened roughly flat but fell through the session, finishing with moderate losses.
Today's stock market... | Motivating AbbVie to make such an expensive acquisition is the fact that Humira -- the world's top-selling drug, accounting for about 60% of the company's revenue -- will have biosimilar competition in the U.S. beginning in 2023. AbbVie believes that it can find $2 billion in annual cost savings and that the combined c... | As for individual stocks, AbbVie (NYSE: ABBV) announced plans to buy Allergan (NYSE: AGN), and Lennar (NYSE: LEN) reported quarterly results. AbbVie wants to acquire Allergan in the latest pharma megadeal AbbVie announced it plans to buy Botox maker Allergan in a deal worth $63 billion, but AbbVie investors panned the ... | As for individual stocks, AbbVie (NYSE: ABBV) announced plans to buy Allergan (NYSE: AGN), and Lennar (NYSE: LEN) reported quarterly results. AbbVie wants to acquire Allergan in the latest pharma megadeal AbbVie announced it plans to buy Botox maker Allergan in a deal worth $63 billion, but AbbVie investors panned the ... | AbbVie wants to acquire Allergan in the latest pharma megadeal AbbVie announced it plans to buy Botox maker Allergan in a deal worth $63 billion, but AbbVie investors panned the move, sending its shares down 16.3%. As for individual stocks, AbbVie (NYSE: ABBV) announced plans to buy Allergan (NYSE: AGN), and Lennar (NY... |
24,958 | 2019-06-25 00:00:00 UTC | Nasdaq Today: Hard to Keep Track of the Losers | ABBV | https://www.nasdaq.com/articles/nasdaq-today%3A-hard-to-keep-track-of-the-losers-2019-06-25 | null | null | Monday might have been a sleepy session, but on Tuesday, we fell out of bed. We had a mega biotech deal to shake things up, while stocks continue to fluctuate ahead of the G20 meeting. So what led to the roughly 1.5% drop in the Nasdaq today?
Source: Shutterstock
Sorting Out the Macro
We said it the other day, but it b... | AbbVie (NYSE:) is scooping up Allergan (NYSE:) in a $63 billion cash-and-stock deal. AGN rallied 26%, while ABBV fell 15%. Source: Shutterstock Sorting Out the Macro We said it the other day, but it bears repeating: Investors are not navigating a normal period of time. | AbbVie (NYSE:) is scooping up Allergan (NYSE:) in a $63 billion cash-and-stock deal. AGN rallied 26%, while ABBV fell 15%. Names like Shopify (NASDAQ:), which fell over 8%, as well as Roku (NASDAQ:), Trade Desk (NASDAQ:), Twilio (NYSE:) and others all took it on the chin Tuesday. | AbbVie (NYSE:) is scooping up Allergan (NYSE:) in a $63 billion cash-and-stock deal. AGN rallied 26%, while ABBV fell 15%. Stocks like Starbucks (NASDAQ:), KLA-Tencor (NASDAQ:) and Walgreens (NASDAQ:), all of which closed higher on the day. | AbbVie (NYSE:) is scooping up Allergan (NYSE:) in a $63 billion cash-and-stock deal. AGN rallied 26%, while ABBV fell 15%. This also comes just a few days ahead of the G20 summit, where investors are hopeful that the U.S. and China can take some meaningful steps toward a trade deal. |
24,959 | 2019-06-25 00:00:00 UTC | 5 Top Stock Trades for Wednesday — AGN, ABBV, FDX, MSFT, BB | ABBV | https://www.nasdaq.com/articles/5-top-stock-trades-for-wednesday-agn-abbv-fdx-msft-bb-2019-06-25 | null | null | It was a slippery slope in the markets on Tuesday, with equities breaking lower. By lunch the PowerShares QQQ ETF (NASDAQ:) was down by 1.5%, while the S&P 500 and Dow Jones carried losses of roughly 75 basis points. In light of that action though, we surely found some top stock trades to watch.
Top Stock Trades for T... | Top Stock Trades for Tomorrow #2: AbbVie ABBV dropped over 15% and isn’t showing many signs of life. Now it’s Allergan’s (NYSE:) turn, which is being acquired by AbbVie (NYSE:). comes in a cash and stock format, with AGN shareholders receiving $120.30 per share in cash and .866 shares of ABBV for each share of AGN they... | Top Stock Trades for Tomorrow #2: AbbVie ABBV dropped over 15% and isn’t showing many signs of life. Now it’s Allergan’s (NYSE:) turn, which is being acquired by AbbVie (NYSE:). comes in a cash and stock format, with AGN shareholders receiving $120.30 per share in cash and .866 shares of ABBV for each share of AGN they... | comes in a cash and stock format, with AGN shareholders receiving $120.30 per share in cash and .866 shares of ABBV for each share of AGN they own. Well, since the cash portion is only for ~$120 per share, the rest of the deal price depends on ABBV stock price. Now it’s Allergan’s (NYSE:) turn, which is being acquired ... | comes in a cash and stock format, with AGN shareholders receiving $120.30 per share in cash and .866 shares of ABBV for each share of AGN they own. Now it’s Allergan’s (NYSE:) turn, which is being acquired by AbbVie (NYSE:). Well, since the cash portion is only for ~$120 per share, the rest of the deal price depends on... |
24,960 | 2019-06-25 00:00:00 UTC | Health Care Sector Update for 06/25/2019: XNCR,BPMX,AGN,ABBV,CNAT,NVS,HF | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-06-25-2019%3A-xncrbpmxagnabbvcnatnvshf-2019-06-25 | null | null | Top Health Care Stocks
JNJ +0.97%
PFE +0.29%
ABT -0.28%
MRK -0.11%
AMGN +0.12%
Health care stocks still were edging lower in late trade, including a slightly more than 0.2% decline for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were down almost 0.3% as a group. The Nasdaq Biote... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. (-) BioPharmX (BPMX) was down 8.5% in late trade after earlier ... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Health care stocks still were edging lower in late trade, inclu... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Health care stocks still were edging lower in late trade, inclu... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. The Nasdaq Biotechnology index was climbing nearly 0.1%. Among ... |
24,961 | 2019-06-25 00:00:00 UTC | 3 Biopharma Stocks to Buy for Income | ABBV | https://www.nasdaq.com/articles/3-biopharma-stocks-to-buy-for-income-2019-06-25 | null | null | Many investors are increasingly looking to generate safe income from dividend stocks. In general, big blue-chip stocks tend to be consistently generous dividend payers. And biopharma companies — when they’re established enough to offer payouts — have traditionally been seen as relatively safe dividend investments. Ther... | Therefore, today I’d like to discuss the outlook for three such stocks, namely GlaxoSmithKline (NYSE:), AbbVie (NYSE:), and Johnson & Johnson (NYSE:). Despite competitive pressures from other big pharma and biotech companies, GSK, ABBV, and JNJ stocks have strong balance sheets, proactive management and several importa... | Despite competitive pressures from other big pharma and biotech companies, GSK, ABBV, and JNJ stocks have strong balance sheets, proactive management and several important drugs in the pipeline that are likely to keep them ahead of the competition. Therefore, today I’d like to discuss the outlook for three such stocks,... | Despite competitive pressures from other big pharma and biotech companies, GSK, ABBV, and JNJ stocks have strong balance sheets, proactive management and several important drugs in the pipeline that are likely to keep them ahead of the competition. Therefore, today I’d like to discuss the outlook for three such stocks,... | AbbVie (ABBV) Source: Shutterstock AbbVie is a $115-billion-market-cap biopharma stock, but shares have been in a downtrend for almost a year, especially following the earnings report on April 25. Since its spinoff from Abbott Laboratories, ABBV has increased dividends every year — a trend that is likely to continue. T... |
24,962 | 2019-06-25 00:00:00 UTC | Mid-Afternoon Market Update: NASDAQ Down 1.5%; Acer Therapeutics Shares Slide | ABBV | https://www.nasdaq.com/articles/mid-afternoon-market-update%3A-nasdaq-down-1.5-acer-therapeutics-shares-slide-2019-06-25 | null | null | Toward the end of trading Tuesday, the Dow traded down 0.71% to 26,536.70 while the NASDAQ fell 1.5% to 7,884.88. The S&P also fell, dropping 0.87% to 2,919.76.
Leading and Lagging Sectors
Materials shares rose 0.2% on Tuesday. Meanwhile, top gainers in the sector included New Gold Inc. (NYSE: NGD), up 8%, and Neenah, ... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Equities Trading UP Pyxus International, Inc. (NYSE: PYX) shares shot up 23% to $16.52 after Imperia... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. The company reported quarterly sales of $5.6 billion, which beat the analyst consensus estimate of $... | Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. In trading on Tuesday, communication services shares fell 1.3%. | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Leading and Lagging Sectors Materials shares rose 0.2% on Tuesday. |
24,963 | 2019-06-25 00:00:00 UTC | Health Care Sector Update for 06/25/2019: BPMX,AGN,ABBV,CNAT,NVS | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-06-25-2019%3A-bpmxagnabbvcnatnvs-2019-06-25-0 | null | null | (Corrects percentage change higher for BioPharmX)
Top Health Care Stocks
JNJ +0.58%
PFE +0.32%
ABT -0.03%
MRK -0.66%
AMGN +0.35%
Health care stocks were little changed in recent trade, including a fractional loss for the NYSE Health Care Index while shares of health care companies in the S&P 500 were up slightly as a g... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Among health care stocks moving on news: (-) BioPharmX (BPMX) w... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. (Corrects percentage change higher for BioPharmX) Top Health Ca... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Health care stocks were little changed in recent trade, includi... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. The Nasdaq Biotechnology index was climbing 0.7%. Among health ... |
24,964 | 2019-06-25 00:00:00 UTC | Health Care Sector Update for 06/25/2019: BPMX,AGN,ABBV,CNAT,NVS | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-06-25-2019%3A-bpmxagnabbvcnatnvs-2019-06-25 | null | null | Top Health Care Stocks
JNJ +0.58%
PFE +0.32%
ABT -0.03%
MRK -0.66%
AMGN +0.35%
Health care stocks were little changed in recent trade, including a fractional loss for the NYSE Health Care Index while shares of health care companies in the S&P 500 were up slightly as a group. The Nasdaq Biotechnology index was climbing ... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Among health care stocks moving on news: (-) BioPharmX (BPMX) w... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Top Health Care Stocks Health care stocks were little changed i... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. Health care stocks were little changed in recent trade, includi... | In other sector news: (+) Allergan (AGN) climbed as much as 30% during Tuesday trading after the Irish drugmaker agreed to a $63 billion buyout offer from AbbVie (ABBV), which will swap $120.30 in cash and 0.8660 of an AbbVie share for each Allergan share. The Nasdaq Biotechnology index was climbing 0.7%. Among health ... |
24,965 | 2019-06-25 00:00:00 UTC | Mid-Day Market Update: Allergan Jumps On Acquisition News; Conatus Pharmaceuticals Shares Plunge | ABBV | https://www.nasdaq.com/articles/mid-day-market-update%3A-allergan-jumps-on-acquisition-news-conatus-pharmaceuticals-shares | null | null | Midway through trading Tuesday, the Dow traded down 0.38% to 26624.77 while the NASDAQ fell 0.95% to 7,929.49. The S&P also fell, dropping 0.55% to 2,929.04.
Leading and Lagging Sectors
Health care shares slipped by just 0.08% on Tuesday. Meanwhile, top gainers in the sector included Allergan plc (NYSE: AGN), up 26%, a... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Equities Trading UP Pyxus International, Inc. (NYSE: PYX) shares shot up 27% to $17.05 after Imperia... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. The company reported quarterly sales of $5.6 billion, which beat the analyst consensus estimate of $... | Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Midway through trading Tuesday, the Dow traded down 0.38% to 26624.77 while the NASDAQ fell 0.95% to... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Midway through trading Tuesday, the Dow traded down 0.38% to 26624.77 while the NASDAQ fell 0.95% to... |
24,966 | 2019-06-25 00:00:00 UTC | AbbVie-Allergan Deal: AGN Stock Soars on $63 Billion Buyout | ABBV | https://www.nasdaq.com/articles/abbvie-allergan-deal%3A-agn-stock-soars-on-%2463-billion-buyout-2019-06-25 | null | null | News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday.
Source:
AbbVie (NYSE:) has announced a new deal that will have it acquiring Allergan (NYSE:) for a total value of $63 billion. The company will be using a mix of cash and stock to acquire all outstanding shares of AGN stock.
The AbbVie-Allergan de... | News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday. If the AbbVie-Allergan deal reaches completion, it will leave ABBV shareholders controlling a majority of the company. Source: AbbVie (NYSE:) has announced a new deal that will have it acquiring Allergan (NYSE:) for a total value of $63 billion. | The AbbVie-Allergan deal will have the former offering up $120.30 in cash and 0.8660 ABBV shares for each share of AGN stock. If the AbbVie-Allergan deal reaches completion, it will leave ABBV shareholders controlling a majority of the company. The AbbVie-Allergan deal will have ABBV continuing to control the company. | The AbbVie-Allergan deal will have the former offering up $120.30 in cash and 0.8660 ABBV shares for each share of AGN stock. News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday. Source: AbbVie (NYSE:) has announced a new deal that will have it acquiring Allergan (NYSE:) for a total value of $63 bil... | This AbbVie-Allergan deal will also have the two companies seeing synergies as they come together. The AbbVie-Allergan deal will have ABBV continuing to control the company. ABBV stock was down 15% and AGN stock was up 26% as of noon Tuesday. |
24,967 | 2019-06-25 00:00:00 UTC | Is The AbbVie-Allergan Deal as Bad for AbbVie as the Market Seems to Think? | ABBV | https://www.nasdaq.com/articles/is-the-abbvie-allergan-deal-as-bad-for-abbvie-as-market-seems-to-think-2019-06-25 | null | null | B
ack in January, I said that “elephant season” had opened for pharma companies, after the announcement that Bristol Myers Squib (BMY) was buying Celgene. By that, I meant that we could expect more big mergers and acquisitions this year, a prediction that came true this morning with the announcement that AbbVie (ABBV) ... | By that, I meant that we could expect more big mergers and acquisitions this year, a prediction that came true this morning with the announcement that AbbVie (ABBV) is finalizing a deal to buy Allergan (AGN). A move of some kind by AbbVie is not unexpected, given that the maker of the blockbuster drug Humira has come u... | By that, I meant that we could expect more big mergers and acquisitions this year, a prediction that came true this morning with the announcement that AbbVie (ABBV) is finalizing a deal to buy Allergan (AGN). A move of some kind by AbbVie is not unexpected, given that the maker of the blockbuster drug Humira has come u... | By that, I meant that we could expect more big mergers and acquisitions this year, a prediction that came true this morning with the announcement that AbbVie (ABBV) is finalizing a deal to buy Allergan (AGN). There is, of course, no guarantee that this will prove to be a good deal, but with all the bad possibilities ge... | There is, of course, no guarantee that this will prove to be a good deal, but with all the bad possibilities getting priced in over the next few days there will be an opportunity in ABBV for those who take a slightly longer view. By that, I meant that we could expect more big mergers and acquisitions this year, a predi... |
24,968 | 2019-06-25 00:00:00 UTC | Stock Market News: AbbVie Bets Big; Can Microsoft Stay on Top? | ABBV | https://www.nasdaq.com/articles/stock-market-news%3A-abbvie-bets-big-can-microsoft-stay-on-top-2019-06-25 | null | null | Tuesday morning brought modest declines to the stock market, falling back from near-record levels as investors tried to get a handle on a wide variety of issues. Fears that the U.S. economy could fall into recession if the Federal Reserve doesn't intervene seemed to gain momentum, pushing 10-year Treasury bond yields b... | With its blockbuster drug Humira looking ahead at a downward spiral in sales from patent expirations and greater competition, AbbVie had to take steps to bolster its growth prospects. In the gap between earnings seasons, major corporate moves take on greater importance, and today, AbbVie (NYSE: ABBV) announced a huge d... | In the gap between earnings seasons, major corporate moves take on greater importance, and today, AbbVie (NYSE: ABBV) announced a huge deal to acquire Allergan (NYSE: AGN) that many investors seemed not to like. Under the terms of the merger agreement, AbbVie will pay $120.30 in cash and 0.8660 AbbVie shares for every ... | AbbVie pays up for growth Shares of AbbVie sank 15% after the pharma giant said that it would buy industry peer Allergan. Under the terms of the merger agreement, AbbVie will pay $120.30 in cash and 0.8660 AbbVie shares for every Allergan share investors own. In the gap between earnings seasons, major corporate moves t... | AbbVie pays up for growth Shares of AbbVie sank 15% after the pharma giant said that it would buy industry peer Allergan. Under the terms of the merger agreement, AbbVie will pay $120.30 in cash and 0.8660 AbbVie shares for every Allergan share investors own. In the gap between earnings seasons, major corporate moves t... |
24,969 | 2019-06-25 00:00:00 UTC | Why AbbVie Stock Is Sinking and Allergan Is Soaring Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-is-sinking-and-allergan-is-soaring-today-2019-06-25 | null | null | What happened
Shares of AbbVie (NYSE: ABBV) were sinking by 14.8% as of 10:38 a.m. EDT on Tuesday while shares of Allergan (NYSE: AGN) were soaring by 26.7%. These big moves came after AbbVie announced plans to acquire Allergan for $63 billion. Investors clearly didn't like AbbVie's decision to buy the Irish drugmaker,... | Investors clearly didn't like AbbVie's decision to buy the Irish drugmaker, but it was great news for Allergan's shareholders. AbbVie's shares were down year to date even before the Allergan announcement as investors fretted over declining sales of the company's top-selling drug Humira. Assuming the deal is finalized, ... | What happened Shares of AbbVie (NYSE: ABBV) were sinking by 14.8% as of 10:38 a.m. EDT on Tuesday while shares of Allergan (NYSE: AGN) were soaring by 26.7%. These big moves came after AbbVie announced plans to acquire Allergan for $63 billion. Investors clearly didn't like AbbVie's decision to buy the Irish drugmaker,... | AbbVie's shares were down year to date even before the Allergan announcement as investors fretted over declining sales of the company's top-selling drug Humira. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. What happened Shares of AbbVie (NYSE: ABBV) were sinking by 1... | What happened Shares of AbbVie (NYSE: ABBV) were sinking by 14.8% as of 10:38 a.m. EDT on Tuesday while shares of Allergan (NYSE: AGN) were soaring by 26.7%. These big moves came after AbbVie announced plans to acquire Allergan for $63 billion. Investors clearly didn't like AbbVie's decision to buy the Irish drugmaker,... |
24,970 | 2019-06-25 00:00:00 UTC | DGRO, VZ, ABBV, MRK: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/dgro-vz-abbv-mrk%3A-large-inflows-detected-at-etf-2019-06-25 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $158.8 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 199,750... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 15.1%, and Merck & Co Inc (Symbol: MRK) is higher by about 0.4%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the o... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 15.1%, and Merck & Co Inc (Symbol: MRK) is higher by about 0.4%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the o... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 15.1%, and Merck & Co Inc (Symbol: MRK) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cover... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is off about 15.1%, and Merck & Co Inc (Symbol: MRK) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cover... |
24,971 | 2019-06-25 00:00:00 UTC | The 10 Biggest Biotech Stocks | ABBV | https://www.nasdaq.com/articles/the-10-biggest-biotech-stocks-2019-06-25 | null | null | If you're looking for a way to beat the market over the long run, biotech stocks look like a pretty good option. Over the last 10 years, the SPDR S&P Biotech ETF (NYSEMKT: XBI), which holds positions in more than 100 biotech stocks, has nearly doubled the performance of the S&P 500 Index.
Some investors are leery of bi... | The company's hepatitis C virus (HCV) franchise continues to generate billions of dollars in revenue annually, although sales have dropped as Gilead and its main rival AbbVie battle each other for fewer new patients. AbbVie AbbVie is another big pharma that qualifies as a biotech thanks primarily to its biologic immuno... | AbbVie AbbVie is another big pharma that qualifies as a biotech thanks primarily to its biologic immunology drug Humira. In 2018, Humira ranked as the top-selling drug in the world and generated 61% of AbbVie's total revenue. The good news for AbbVie is that it has several potential products to offset the declining sal... | AbbVie AbbVie is another big pharma that qualifies as a biotech thanks primarily to its biologic immunology drug Humira. In 2018, Humira ranked as the top-selling drug in the world and generated 61% of AbbVie's total revenue. The good news for AbbVie is that it has several potential products to offset the declining sal... | AbbVie AbbVie is another big pharma that qualifies as a biotech thanks primarily to its biologic immunology drug Humira. In 2018, Humira ranked as the top-selling drug in the world and generated 61% of AbbVie's total revenue. The good news for AbbVie is that it has several potential products to offset the declining sal... |
24,972 | 2019-06-25 00:00:00 UTC | S&P 500 Movers: ABBV, AGN | ABBV | https://www.nasdaq.com/articles/sp-500-movers%3A-abbv-agn-2019-06-25 | null | null | In early trading on Tuesday, shares of Allergan (AGN) topped the list of the day's best performing components of the S&P 500 index, trading up 27.2%. Year to date, Allergan registers a 23.3% gain.
And the worst performing S&P 500 component thus far on the day is AbbVie (ABBV), trading down 14.5%. AbbVie is lower by abo... | And the worst performing S&P 500 component thus far on the day is AbbVie (ABBV), trading down 14.5%. VIDEO: S&P 500 Movers: ABBV, AGN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie is lower by about 27.2% looking at the year t... | And the worst performing S&P 500 component thus far on the day is AbbVie (ABBV), trading down 14.5%. VIDEO: S&P 500 Movers: ABBV, AGN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie is lower by about 27.2% looking at the year t... | And the worst performing S&P 500 component thus far on the day is AbbVie (ABBV), trading down 14.5%. AbbVie is lower by about 27.2% looking at the year to date performance. VIDEO: S&P 500 Movers: ABBV, AGN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect th... | And the worst performing S&P 500 component thus far on the day is AbbVie (ABBV), trading down 14.5%. AbbVie is lower by about 27.2% looking at the year to date performance. VIDEO: S&P 500 Movers: ABBV, AGN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect th... |
24,973 | 2019-06-25 00:00:00 UTC | Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Estimates | ABBV | https://www.nasdaq.com/articles/mid-morning-market-update%3A-markets-open-lower-lennar-tops-q2-estimates-2019-06-25 | null | null | Following the market opening Tuesday, the Dow traded down 0.27% to 26,656.50 while the NASDAQ fell 0.33% to 7,979.12. The S&P also fell, dropping 0.21% to 2,939.19.
Leading and Lagging Sectors
Health care shares gained 0.4% on Tuesday. Meanwhile, top gainers in the sector included Allergan plc (NYSE: AGN), up 27%, and ... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Equities Trading UP Pyxus International, Inc. (NYSE: PYX) shares shot up 34% to $18.00 after Imperia... | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Meanwhile, top gainers in the sector included Allergan plc (NYSE: AGN), up 27%, and Xencor, Inc. (NA... | Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. In trading on Tuesday, communication services shares fell 0.8%. | AbbVie Inc (NYSE: ABBV) reached a deal to acquire Allergan for $63 billion. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share. Meanwhile, top gainers in the sector included Allergan plc (NYSE: AGN), up 27%, and Xencor, Inc. (NA... |
24,974 | 2019-06-25 00:00:00 UTC | AbbVie’s $63 Billion Mistake | ABBV | https://www.nasdaq.com/articles/abbvies-%2463-billion-mistake-2019-06-25 | null | null | AbbVie (NYSE: ABBV) announced this morning its intention to acquire Irish drugmaker Allergan (NYSE: AGN) in a stock-and-cash deal for $63 billion (or $188.24 per share). More specifically, AbbVie is offering Allergan shareholders $120.30 in cash and 0.866 AbbVie shares per share of Allergan they currently own.
AbbVie a... | AbbVie has been working hard to plug that hole with a variety of autoimmune drugs, hoping to shore up its market position as Humira's inevitable decline comes into more focus. AbbVie's autoimmune drug Skyrizi recently received FDA approval for psoriasis and is in phase 3 testing for a variety of other indications, incl... | More specifically, AbbVie is offering Allergan shareholders $120.30 in cash and 0.866 AbbVie shares per share of Allergan they currently own. (And for what it's worth, given that Allergan anticipates non-GAAP net income per share of $3.50 this year at the midpoint, AbbVie's $188.24-per-share proposed buyout price looks... | More specifically, AbbVie is offering Allergan shareholders $120.30 in cash and 0.866 AbbVie shares per share of Allergan they currently own. And the price is too high AbbVie is proposing to acquire Allergan for $63 billion, just north of a four-times multiple on its 2018 revenue. AbbVie (NYSE: ABBV) announced this mor... | More specifically, AbbVie is offering Allergan shareholders $120.30 in cash and 0.866 AbbVie shares per share of Allergan they currently own. AbbVie (NYSE: ABBV) announced this morning its intention to acquire Irish drugmaker Allergan (NYSE: AGN) in a stock-and-cash deal for $63 billion (or $188.24 per share). AbbVie a... |
24,975 | 2019-06-24 00:00:00 UTC | 3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-medtronic-paychex-and-abbvie-2019-06-24 | null | null | Traders were willing to buoy the market up to April’s record highs on Thursday of last week, but no more. The S&P 500 lost 0.13% of its value on Friday, leaving most market participants wondering if the surprisingly bullish June to date is nothing more than a mirage.
Source:
Altria Group (NYSE:) was arguably the bigges... | Headed into Monday’s trading, however, it’s the stock charts of AbbVie (NYSE:), Paychex (NASDAQ:) and Medtronic (NYSE:) that merit the closest looks. AbbVie (ABBV) In late April it was noted that AbbVie was being , formed by a horizontal support line that had been holding up since October, and a falling resistance line... | Headed into Monday’s trading, however, it’s the stock charts of AbbVie (NYSE:), Paychex (NASDAQ:) and Medtronic (NYSE:) that merit the closest looks. AbbVie (ABBV) In late April it was noted that AbbVie was being , formed by a horizontal support line that had been holding up since October, and a falling resistance line... | Headed into Monday’s trading, however, it’s the stock charts of AbbVie (NYSE:), Paychex (NASDAQ:) and Medtronic (NYSE:) that merit the closest looks. AbbVie (ABBV) In late April it was noted that AbbVie was being , formed by a horizontal support line that had been holding up since October, and a falling resistance line... | Headed into Monday’s trading, however, it’s the stock charts of AbbVie (NYSE:), Paychex (NASDAQ:) and Medtronic (NYSE:) that merit the closest looks. AbbVie (ABBV) In late April it was noted that AbbVie was being , formed by a horizontal support line that had been holding up since October, and a falling resistance line... |
24,976 | 2019-06-21 00:00:00 UTC | Daily Dividend Report: WASH, MDT, CL, ABBV, UDR | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-wash-mdt-cl-abbv-udr-2019-06-21 | null | null | The Board of Directors of Washington Trust Bancorp, today declared a quarterly dividend of $0.51 cents per share for the quarter ending June 30, 2019. The declaration represents a $0.04 per share increase over the most recent quarterly dividend rate. The dividend will be paid July 12, 2019 to shareholders of record on ... | The board of directors of AbbVie declared a quarterly cash dividend of $1.07 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 168 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 co... | The board of directors of AbbVie declared a quarterly cash dividend of $1.07 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 168 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 co... | The board of directors of AbbVie declared a quarterly cash dividend of $1.07 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 168 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 co... | The board of directors of AbbVie declared a quarterly cash dividend of $1.07 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 168 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 co... |
24,977 | 2019-06-20 00:00:00 UTC | 3 Drugs Under FDA Review With Blockbuster Potential | ABBV | https://www.nasdaq.com/articles/3-drugs-under-fda-review-with-blockbuster-potential-2019-06-20 | null | null | Being the first drugmaker to develop a therapy attacking a new target in cells can result in blockbuster sales. But other companies can wrestle that market share away from the first-in-class drugs with follow-on drugs going after the same targets if the new drugs can provide better safety, efficacy, or dosing than the ... | JAK of all trades Upadacitinib, which was licensed from Galapagos (NASDAQ: GLPG), is a Janus kinase 1 (JAK1) inhibitor that AbbVie is developing for a range of diseases in which an overactive immune system leads to inflammation. While AbbVie has some work to do to take away market share from Pfizer and Eli Lilly's (NYS... | While AbbVie has some work to do to take away market share from Pfizer and Eli Lilly's (NYSE: LLY) JAK inhibitor Olumiant -- and additional upcoming competition from Gilead Sciences' (NASDAQ: GILD) filgotinib -- there's some evidence that upadacitinib might work better than Xeljanz based on their respective studies com... | While AbbVie has some work to do to take away market share from Pfizer and Eli Lilly's (NYSE: LLY) JAK inhibitor Olumiant -- and additional upcoming competition from Gilead Sciences' (NASDAQ: GILD) filgotinib -- there's some evidence that upadacitinib might work better than Xeljanz based on their respective studies com... | JAK of all trades Upadacitinib, which was licensed from Galapagos (NASDAQ: GLPG), is a Janus kinase 1 (JAK1) inhibitor that AbbVie is developing for a range of diseases in which an overactive immune system leads to inflammation. While AbbVie has some work to do to take away market share from Pfizer and Eli Lilly's (NYS... |
24,978 | 2019-06-19 00:00:00 UTC | Is Abbott Laboratories a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbott-laboratories-a-buy-2019-06-19 | null | null | In the world of investing, sometimes boring is good. Diversified healthcare company Abbott Laboratories (NYSE: ABT) has been rewarding its shareholders with solid growth without the ups and downs that pharmaceutical stocks often deliver. Even though the stock is hitting new highs, is it a buy now?
Abbott Labs split int... | Abbott Labs split into two companies at the beginning of 2013 when it spun off its research-based pharmaceutical business, which became AbbVie. The rationale for the division was that AbbVie's business would be high-risk and high-reward with high dividends, while Abbott Labs would be a diversified healthcare business n... | The rationale for the division was that AbbVie's business would be high-risk and high-reward with high dividends, while Abbott Labs would be a diversified healthcare business not subject to the risks of bringing new drugs to market. Abbott Labs split into two companies at the beginning of 2013 when it spun off its rese... | Abbott Labs split into two companies at the beginning of 2013 when it spun off its research-based pharmaceutical business, which became AbbVie. The rationale for the division was that AbbVie's business would be high-risk and high-reward with high dividends, while Abbott Labs would be a diversified healthcare business n... | The rationale for the division was that AbbVie's business would be high-risk and high-reward with high dividends, while Abbott Labs would be a diversified healthcare business not subject to the risks of bringing new drugs to market. Abbott Labs split into two companies at the beginning of 2013 when it spun off its rese... |
24,979 | 2019-06-17 00:00:00 UTC | Notable ETF Inflow Detected - DGRO, VZ, ABBV, MRK | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-dgro-vz-abbv-mrk-2019-06-17 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $70.2 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 197,900,... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 1.7%, AbbVie Inc (Symbol: ABBV) is up about 0.2%, and Merck & Co Inc (Symbol: MRK) is up by about 0.4%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one ye... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 1.7%, AbbVie Inc (Symbol: ABBV) is up about 0.2%, and Merck & Co Inc (Symbol: MRK) is up by about 0.4%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one ye... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 1.7%, AbbVie Inc (Symbol: ABBV) is up about 0.2%, and Merck & Co Inc (Symbol: MRK) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... | Among the largest underlying components of DGRO, in trading today Verizon Communications Inc (Symbol: VZ) is down about 1.7%, AbbVie Inc (Symbol: ABBV) is up about 0.2%, and Merck & Co Inc (Symbol: MRK) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... |
24,980 | 2019-06-17 00:00:00 UTC | Why AbbVie Is a Retiree's Dream Stock | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-retirees-dream-stock-2019-06-17 | null | null | What does every retired investor want in a stock? You'd definitely expect a strong dividend to be ranked close to the top of the list. Retired investors would also want to make sure that the company was in good shape to keep those dividends flowing, with dividend growth a nice bonus. And it wouldn't hurt for the stock ... | Including the time that it was still part of its parent company, Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 consecutive years. But even though Humira generates 57% of AbbVie's total revenue, the company isn't worried about the falling sales for its top drug. Major healthcare system changes in the... | Including the time that it was still part of its parent company, Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 consecutive years. Risks offset by an attractive valuation AbbVie faces some risks. AbbVie provides a strong dividend, solid growth prospects, and an attractive valuation. | A fantastic -- and growing -- dividend Let's start with AbbVie's dividend. Based on AbbVie's current dividend level and its history of dividend growth, I fully expect that the dividend will double within the next seven years. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stoc... | Including the time that it was still part of its parent company, Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 consecutive years. Based on AbbVie's current dividend level and its history of dividend growth, I fully expect that the dividend will double within the next seven years. But one stock that ... |
24,981 | 2019-06-16 00:00:00 UTC | 3 Cheap Drug Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-cheap-drug-stocks-you-can-buy-right-now-2019-06-16 | null | null | Sure, the bull market is now more than 10 years old. Stock valuations, in general, have risen to lofty levels. Some investors might be tempted to sit on the sidelines until better bargains can be found.
The reality, though, is that there are currently quite a few stocks that look like bargains. Many pharma stocks haven... | Three cheap drug stocks that you can buy right now are AbbVie (NYSE: ABBV), Alexion Pharmaceuticals (NASDAQ: ALXN), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie AbbVie's shares trade at only 8.3 times expected earnings. AbbVie claims the No. | Three cheap drug stocks that you can buy right now are AbbVie (NYSE: ABBV), Alexion Pharmaceuticals (NASDAQ: ALXN), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie AbbVie's shares trade at only 8.3 times expected earnings. AbbVie claims the No. | Three cheap drug stocks that you can buy right now are AbbVie (NYSE: ABBV), Alexion Pharmaceuticals (NASDAQ: ALXN), and Vertex Pharmaceuticals (NASDAQ: VRTX). See the 10 stocks *Stock Advisor returns as of March 1, 2019 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. AbbVie AbbVie's shares trade at onl... | With Humira generating 57% of AbbVie's total revenue, there are concerns about whether the company will be able to replace the declining sales from its top drug. Three cheap drug stocks that you can buy right now are AbbVie (NYSE: ABBV), Alexion Pharmaceuticals (NASDAQ: ALXN), and Vertex Pharmaceuticals (NASDAQ: VRTX).... |
24,982 | 2019-06-15 00:00:00 UTC | 5 Biggest Blockbuster Drugs of the Future | ABBV | https://www.nasdaq.com/articles/5-biggest-blockbuster-drugs-of-the-future-2019-06-15 | null | null | Things change relatively quickly in the pharmaceutical world. Even a best-selling drug can only hold its top spot for a while before its sales fade and a newer treatment takes its place.
EvaluatePharma's recently released World Preview 2019, Outlook to 2024 report underscores this point. The market research company pr... | AbbVie (NYSE: ABBV) faces biosimilar competition for the enormously successful immunology drug in Europe already, and will battle biosimilars in the U.S. beginning in 2023. But Humira will keep making plenty of money for AbbVie for a while longer. AbbVie partners with Johnson & Johnson (NYSE: JNJ) in marketing cancer d... | AbbVie partners with Johnson & Johnson (NYSE: JNJ) in marketing cancer drug Imbruvica, which moves up from No. AbbVie (NYSE: ABBV) faces biosimilar competition for the enormously successful immunology drug in Europe already, and will battle biosimilars in the U.S. beginning in 2023. But Humira will keep making plenty o... | AbbVie (NYSE: ABBV) faces biosimilar competition for the enormously successful immunology drug in Europe already, and will battle biosimilars in the U.S. beginning in 2023. But Humira will keep making plenty of money for AbbVie for a while longer. AbbVie partners with Johnson & Johnson (NYSE: JNJ) in marketing cancer d... | AbbVie (NYSE: ABBV) faces biosimilar competition for the enormously successful immunology drug in Europe already, and will battle biosimilars in the U.S. beginning in 2023. But Humira will keep making plenty of money for AbbVie for a while longer. AbbVie partners with Johnson & Johnson (NYSE: JNJ) in marketing cancer d... |
24,983 | 2019-06-11 00:00:00 UTC | 10 Smart Dividend Stocks for the Rest of the Year | ABBV | https://www.nasdaq.com/articles/10-smart-dividend-stocks-for-the-rest-of-the-year-2019-06-11 | null | null | The market has managed to back itself away from imminent danger, bouncing back from a relatively serious stumble from a couple of weeks ago. It’s too soon to say stocks will be able to remain out of trouble, though. Aside from a lethargic time of year, the wrong headline could still easily up-end it all.
Or, perhaps th... | AbbVie (ABBV) Source: Shutterstock Dividend Yield: 5.5% Drugmaker AbbVie (NYSE:) has been a tough name to own of late. That clearly puts a countdown timer on ABBV stock and its capacity to pay a dividend, and other Humira-related patents are scheduled to expire in the meantime. It now owns a significant piece of mariju... | AbbVie (ABBV) Source: Shutterstock Dividend Yield: 5.5% Drugmaker AbbVie (NYSE:) has been a tough name to own of late. That clearly puts a countdown timer on ABBV stock and its capacity to pay a dividend, and other Humira-related patents are scheduled to expire in the meantime. Dividend Stocks to Buy: Microsoft (MSFT) ... | AbbVie (ABBV) Source: Shutterstock Dividend Yield: 5.5% Drugmaker AbbVie (NYSE:) has been a tough name to own of late. That clearly puts a countdown timer on ABBV stock and its capacity to pay a dividend, and other Humira-related patents are scheduled to expire in the meantime. Dividend Stocks to Buy: Microsoft (MSFT) ... | AbbVie (ABBV) Source: Shutterstock Dividend Yield: 5.5% Drugmaker AbbVie (NYSE:) has been a tough name to own of late. That clearly puts a countdown timer on ABBV stock and its capacity to pay a dividend, and other Humira-related patents are scheduled to expire in the meantime. Dividend Stocks to Buy: Microsoft (MSFT) ... |
24,984 | 2019-06-10 00:00:00 UTC | Don't Expect CBD Action Anytime Soon | ABBV | https://www.nasdaq.com/articles/dont-expect-cbd-action-anytime-soon-2019-06-10 | null | null | The recent public hearing by the Food & Drug Administration on cannabidiol (CBD) provided little clarity on the regulatory way forward for the marijuana-based compound. Acting FDA commissioner Ned Sharpless said there were "real risks" with using CBD and reiterated that since the agency has approved drugs with CBD as t... | Eliminating the patchwork approach to regulation The FDA sees potential in these compounds, having approved GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, which uses CBD as the active ingredient, as a drug treatment for epilepsy, as well as Marinol from AbbVie (NYSE: ABBV) and Syndros from Insys Therapeutics (NASDAQ: IN... | Eliminating the patchwork approach to regulation The FDA sees potential in these compounds, having approved GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, which uses CBD as the active ingredient, as a drug treatment for epilepsy, as well as Marinol from AbbVie (NYSE: ABBV) and Syndros from Insys Therapeutics (NASDAQ: IN... | Eliminating the patchwork approach to regulation The FDA sees potential in these compounds, having approved GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, which uses CBD as the active ingredient, as a drug treatment for epilepsy, as well as Marinol from AbbVie (NYSE: ABBV) and Syndros from Insys Therapeutics (NASDAQ: IN... | Eliminating the patchwork approach to regulation The FDA sees potential in these compounds, having approved GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, which uses CBD as the active ingredient, as a drug treatment for epilepsy, as well as Marinol from AbbVie (NYSE: ABBV) and Syndros from Insys Therapeutics (NASDAQ: IN... |
24,985 | 2019-06-10 00:00:00 UTC | Better Buy: Eli Lilly vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy%3A-eli-lilly-vs.-abbvie-2019-06-10 | null | null | Eli Lilly (NYSE: LLY) and AbbVie (NYSE: ABBV) are similar-sized major drugmakers. But investors have viewed Lilly much more favorably lately. Its shares have soared 38% over the past 12 months, while AbbVie stock has sunk nearly 23%.
Does this mean that Lilly is the better pick for long-term investors than AbbVie is? N... | As was the case for Lilly, several of AbbVie's late-stage candidates target additional indications for existing drugs, including Imbruvica, Orilissa, Skyrizi, and Venclexta. Eli Lilly (NYSE: LLY) and AbbVie (NYSE: ABBV) are similar-sized major drugmakers. Its shares have soared 38% over the past 12 months, while AbbVie... | As was the case for Lilly, several of AbbVie's late-stage candidates target additional indications for existing drugs, including Imbruvica, Orilissa, Skyrizi, and Venclexta. Wall Street analysts project average annual earnings growth for AbbVie of nearly 8% over the next five years. Eli Lilly (NYSE: LLY) and AbbVie (NY... | The case for AbbVie One drug currently contributes 57% of AbbVie's total revenue. Like Lilly, AbbVie has a relatively new drug that isn't a significant moneymaker yet but could be in the not-too-distant future. As was the case for Lilly, several of AbbVie's late-stage candidates target additional indications for existi... | AbbVie expects peak sales of $2 billion for the drug. As was the case for Lilly, several of AbbVie's late-stage candidates target additional indications for existing drugs, including Imbruvica, Orilissa, Skyrizi, and Venclexta. AbbVie has increased its dividend payout by 168% over the last six years. |
24,986 | 2019-06-07 00:00:00 UTC | iShares Core Dividend Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-dividend-growth-etf-experiences-big-inflow-2019-06-07 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $247.4 million dollar inflow -- that's a 3.4% increase week over week in outstanding units (from 191,550... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Home Depot Inc (Symbol: HD) is up about 0.5%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.5%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price ... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Home Depot Inc (Symbol: HD) is up about 0.5%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.5%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price ... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Home Depot Inc (Symbol: HD) is up about 0.5%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Home Depot Inc (Symbol: HD) is up about 0.5%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... |
24,987 | 2019-06-07 00:00:00 UTC | Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far | ABBV | https://www.nasdaq.com/articles/why-im-sticking-my-3-worst-performing-stocks-2019-so-far-2019-06-07 | null | null | I just checked to see how the stocks that I own are performing. It's not something that I do very often, although I do keep close tabs on the business developments related to each of my positions. Despite the market downturn over the past few weeks, I was pleased to learn that my stocks are doing pretty well overall.
E... | Unique twists AbbVie, Editas, and Pfizer haven't floundered so far this year just because of the political uncertainties related to the U.S. healthcare system. Even worse, AbbVie provided weak guidance for full-year 2019 due to sinking international sales for its top-selling drug Humira, which now faces competition fro... | Even worse, AbbVie provided weak guidance for full-year 2019 due to sinking international sales for its top-selling drug Humira, which now faces competition from biosimilars in Europe. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Keith Speights owns shares of AbbVie, CELG, Editas Medicine, and Pfizer. M... | See the 10 stocks *Stock Advisor returns as of March 1, 2019 Keith Speights owns shares of AbbVie, CELG, Editas Medicine, and Pfizer. My three worst-performing stocks so far in 2019 are AbbVie (NYSE: ABBV), Editas Medicine (NASDAQ: EDIT), and Pfizer (NYSE: PFE). There's another common denominator for AbbVie, Editas, an... | My three worst-performing stocks so far in 2019 are AbbVie (NYSE: ABBV), Editas Medicine (NASDAQ: EDIT), and Pfizer (NYSE: PFE). There's another common denominator for AbbVie, Editas, and Pfizer. In 2017, for example, AbbVie was one of my best-performing stocks, soaring more than 50%. |
24,988 | 2019-05-31 00:00:00 UTC | Notable Friday Option Activity: MSFT, ABBV, LRCX | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-msft-abbv-lrcx-2019-05-31 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Microsoft Corporation (Symbol: MSFT), where a total volume of 109,184 contracts has been traded thus far today, a contract volume which is representative of approximately 10.9 million underlying shares (give... | Particularly high volume was seen for the $90 strike call option expiring August 16, 2019, with 3,557 contracts trading so far today, representing approximately 355,700 underlying shares of ABBV. Below is a chart showing MSFT's trailing twelve month trading history, with the $134 strike highlighted in orange: AbbVie In... | Below is a chart showing MSFT's trailing twelve month trading history, with the $134 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 19,564 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $90 strike highlighted in orange: ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $90 strike highlighted in orange: And Lam Research Corp (Symbol: LRCX) saw options trading volume of 7,996 contracts, representing approximately 799,600 underlying shares or approximately 40.8% of LRCX's average daily trading volume over th... | Below is a chart showing ABBV's trailing twelve month trading history, with the $90 strike highlighted in orange: And Lam Research Corp (Symbol: LRCX) saw options trading volume of 7,996 contracts, representing approximately 799,600 underlying shares or approximately 40.8% of LRCX's average daily trading volume over th... |
24,989 | 2019-05-30 00:00:00 UTC | 3 Top Gene Therapy Stocks That Could Soar | ABBV | https://www.nasdaq.com/articles/3-top-gene-therapy-stocks-that-could-soar-2019-05-30 | null | null | Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually “turning off” the genes causing problems, gene therapy has the potential to change the game when it come... | For gene therapy play Voyager Therapeutics (NASDAQ:), partnerships include biotech giant AbbVie (NYSE:), neurological specialist Neurocrine Biosciences (NASDAQ:) and major pharma stock Sanofi (NASDAQ:). With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize... | For gene therapy play Voyager Therapeutics (NASDAQ:), partnerships include biotech giant AbbVie (NYSE:), neurological specialist Neurocrine Biosciences (NASDAQ:) and major pharma stock Sanofi (NASDAQ:). Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP) Source: Shutterstock Clustered Regularly Interspaced Short Pal... | For gene therapy play Voyager Therapeutics (NASDAQ:), partnerships include biotech giant AbbVie (NYSE:), neurological specialist Neurocrine Biosciences (NASDAQ:) and major pharma stock Sanofi (NASDAQ:). By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually “turning off” th... | For gene therapy play Voyager Therapeutics (NASDAQ:), partnerships include biotech giant AbbVie (NYSE:), neurological specialist Neurocrine Biosciences (NASDAQ:) and major pharma stock Sanofi (NASDAQ:). QURE has seen great success with its gene therapy program for the blood disorder. Voyager Therapeutics (VYGR) Source:... |
24,990 | 2019-05-30 00:00:00 UTC | The Inverted Yield Curve Should Make Investors Pivot, Not Panic | ABBV | https://www.nasdaq.com/articles/inverted-yield-curve-should-make-investors-pivot-not-panic-2019-05-30 | null | null | Investors have sold stocks on nervousness surrounding the inverted yield curve. No inversion this large has occurred , right before the 2008 financial crisis. But don’t indiscriminately slam that “SELL” button just yet. Yield-curve inversions merely indicate recessions rather than predict them.
However, given the lengt... | What makes the cash return more significant is the fact that AbbVie has built a 46-year track record of annual payout hikes that will likely continue. For example, AbbVie (NYSE:) has faced a looming patent expiration on Humira, a key source of revenue. Consequently, ABBV stock trades at a forward P/E ratio of just 8.25... | For example, AbbVie (NYSE:) has faced a looming patent expiration on Humira, a key source of revenue. Consequently, ABBV stock trades at a forward P/E ratio of just 8.25. Moreover, ABBV’s dividend yield stands at about 5.4%. | For example, AbbVie (NYSE:) has faced a looming patent expiration on Humira, a key source of revenue. Consequently, ABBV stock trades at a forward P/E ratio of just 8.25. Moreover, ABBV’s dividend yield stands at about 5.4%. | For example, AbbVie (NYSE:) has faced a looming patent expiration on Humira, a key source of revenue. Consequently, ABBV stock trades at a forward P/E ratio of just 8.25. Moreover, ABBV’s dividend yield stands at about 5.4%. |
24,991 | 2019-05-28 00:00:00 UTC | This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy | ABBV | https://www.nasdaq.com/articles/just-%3A-goldman-sachs-picks-4-big-pharma-stocks-buy-2019-05-28 | null | null | Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking several high-profile Wall Street picks and putting them under the microscope...
Investment banker Goldman Sachs plunged back into ... | Initiating coverage of seven biotech and pharmaceutical companies running nearly the length of the alphabet -- from AbbVie all the way to Pfizer (NYSE: PFE) -- Goldman Sachs had good news for investors: Three of these stocks -- Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and Bristol-Myers Squibb (NYSE: BMY) -... | Initiating coverage of seven biotech and pharmaceutical companies running nearly the length of the alphabet -- from AbbVie all the way to Pfizer (NYSE: PFE) -- Goldman Sachs had good news for investors: Three of these stocks -- Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and Bristol-Myers Squibb (NYSE: BMY) -... | Initiating coverage of seven biotech and pharmaceutical companies running nearly the length of the alphabet -- from AbbVie all the way to Pfizer (NYSE: PFE) -- Goldman Sachs had good news for investors: Three of these stocks -- Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and Bristol-Myers Squibb (NYSE: BMY) -... | Initiating coverage of seven biotech and pharmaceutical companies running nearly the length of the alphabet -- from AbbVie all the way to Pfizer (NYSE: PFE) -- Goldman Sachs had good news for investors: Three of these stocks -- Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and Bristol-Myers Squibb (NYSE: BMY) -... |
24,992 | 2019-05-27 00:00:00 UTC | This 5% Dividend Yield Isn't Good Enough for Me | ABBV | https://www.nasdaq.com/articles/5-dividend-yield-isnt-good-enough-me-2019-05-27 | null | null | The very first stock I ever bought had a 20% dividend yield.
It didn't pan out well for me. The details are a story for another day, but suffice it to say that I fell into the classic trap that catches many income investors: getting excited about a company's juicy yield, and then buying the company for the dividend.
In... | (The gap between the two can be explained by AbbVie taking a $4 billion impairment charge -- which impacts earnings, but not cash -- when it scrapped a major clinical drug in January.) Fortunately for AbbVie (at least in the short term), about three-quarters of Humira's sales are domestic, so most of its revenue is shi... | But I think AbbVie (NYSE: ABBV) has too many problems right now. So, despite its 5% dividend yield, AbbVie isn't worth an investment today. Now, you might think my concern centers on the sustainability of AbbVie's dividend. | Plus, if you measure the dividend by the cash dividend payout ratio (that is, dividing dividends paid by operating cash flow minus capital expenditures), AbbVie achieves a 46% ratio -- a sign that the company's dividend is quite well funded by cash. Although Humira's $19.9 billion in 2018 sales undoubtedly represented ... | Plus, if you measure the dividend by the cash dividend payout ratio (that is, dividing dividends paid by operating cash flow minus capital expenditures), AbbVie achieves a 46% ratio -- a sign that the company's dividend is quite well funded by cash. Fortunately for AbbVie (at least in the short term), about three-quart... |
24,993 | 2019-05-22 00:00:00 UTC | 3 Top Dividend Stocks With Yields Over 5% | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-yields-over-5-2019-05-22 | null | null | High dividend yields are harder to find lately, given the long-running stock market rally. But that scarcity doesn't mean investors have to sacrifice quality to stretch for higher income rates.
Below, we'll look at a few dividend stocks that pay over 5% today, but still look attractive as business investments. Read on... | Read on to see why Ford (NYSE: F), AbbVie (NYSE: ABBV), and Six Flags (NYSE: SIX) all deserve a spot on your income watchlist. No love for this big pharma company Nicholas Rossolillo (AbbVie): The first quarter of 2019 was just OK for AbbVie. The challenges for AbbVie surround its marquee autoimmune disorder treatment ... | Read on to see why Ford (NYSE: F), AbbVie (NYSE: ABBV), and Six Flags (NYSE: SIX) all deserve a spot on your income watchlist. No love for this big pharma company Nicholas Rossolillo (AbbVie): The first quarter of 2019 was just OK for AbbVie. The challenges for AbbVie surround its marquee autoimmune disorder treatment ... | Read on to see why Ford (NYSE: F), AbbVie (NYSE: ABBV), and Six Flags (NYSE: SIX) all deserve a spot on your income watchlist. No love for this big pharma company Nicholas Rossolillo (AbbVie): The first quarter of 2019 was just OK for AbbVie. The challenges for AbbVie surround its marquee autoimmune disorder treatment ... | Read on to see why Ford (NYSE: F), AbbVie (NYSE: ABBV), and Six Flags (NYSE: SIX) all deserve a spot on your income watchlist. No love for this big pharma company Nicholas Rossolillo (AbbVie): The first quarter of 2019 was just OK for AbbVie. The challenges for AbbVie surround its marquee autoimmune disorder treatment ... |
24,994 | 2019-05-21 00:00:00 UTC | Better Buy: AbbVie vs. Pfizer | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-pfizer-2019-05-21 | null | null | Over the last five years, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have both produced market-crushing returns for investors -- that is, when their top-notch dividends are figured into the equation. This year, however, hasn't exactly been kind to either company. Key patent expires and the drug pricing controversy have... | Over the last five years, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have both produced market-crushing returns for investors -- that is, when their top-notch dividends are figured into the equation. The case for AbbVie AbbVie is a company on the cusp of a major metamorphosis. This blanket opposition to AbbVie, though,... | Unfortunately, AbbVie's business development and clinical activities designed to carry it past Humira's decline have come at a steep cost. Over the last five years, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have both produced market-crushing returns for investors -- that is, when their top-notch dividends are figured ... | The simple reason is that Pfizer isn't overly reliant on any one product for top-line growth, whereas AbbVie arguably needs its rheumatoid arthritis candidate to get off to a blistering start to assuage the market's fears over Humira. That may not be fair, but the market has already shown that it doesn't believe in Abb... | Over the last five years, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have both produced market-crushing returns for investors -- that is, when their top-notch dividends are figured into the equation. The case for AbbVie AbbVie is a company on the cusp of a major metamorphosis. This blanket opposition to AbbVie, though,... |
24,995 | 2019-05-21 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-buy-right-now-2019-05-21 | null | null | There's nothing easy about selecting a dividend stock, especially when the market is trading near all-time highs, as it is now. But if you dig deep enough, you can find some great opportunities that combine high yields and compelling investment opportunities. Three that you should be looking at right now, according to ... | And the recent approval of Skyrizi for moderate to severe plaque psoriasis gives AbbVie yet another major growth driver to power past Humira's patent cliff. Three that you should be looking at right now, according to these three Motley Fool contributors, are cellphone giant Verizon (NYSE: VZ), global drugmaker AbbVie (... | Three that you should be looking at right now, according to these three Motley Fool contributors, are cellphone giant Verizon (NYSE: VZ), global drugmaker AbbVie (NYSE: ABBV), and utility bellwether Southern Company (NYSE: SO). A falling knife worth catching George Budwell (AbbVie): AbbVie, a dividend aristocrat, has s... | Three that you should be looking at right now, according to these three Motley Fool contributors, are cellphone giant Verizon (NYSE: VZ), global drugmaker AbbVie (NYSE: ABBV), and utility bellwether Southern Company (NYSE: SO). A falling knife worth catching George Budwell (AbbVie): AbbVie, a dividend aristocrat, has s... | Why should investors give AbbVie a second chance? Three that you should be looking at right now, according to these three Motley Fool contributors, are cellphone giant Verizon (NYSE: VZ), global drugmaker AbbVie (NYSE: ABBV), and utility bellwether Southern Company (NYSE: SO). A falling knife worth catching George Budw... |
24,996 | 2019-05-19 00:00:00 UTC | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big | ABBV | https://www.nasdaq.com/articles/top-5-new-drug-launches-2019-and-biotech-stocks-could-win-big-2019-05-19 | null | null | Every year, biopharmaceutical companies introduce new drugs to the market. Some of these drugs become big winners. Others don't.
Market research company EvaluatePharma analyzed all of the drugs that could launch in 2019. The company then projected how much each drug could potentially generate by 2024. Alexion Pharmaceu... | AbbVie is also evaluating upadacitinib in late-stage clinical studies targeting atopic dermatitis, Crohn's disease, psoriatic arthritis, and ulcerative colitis. AbbVie won FDA approval for risankizumab in April for treating plaque psoriasis, and the company launched the drug under the brand name Skyrizi earlier this mo... | Risankizumab (AbbVie) Upadacitinib wasn't AbbVie's only immunology drug to make EvaluatePharma's top five list. Alexion Pharmaceuticals (NASDAQ: ALXN), AbbVie (NYSE: ABBV), Aimmune Therapeutics (NASDAQ: AIMT), and bluebird bio (NASDAQ: BLUE) came out on top in EvaluatePharma's ranking of the top five new drug launches ... | Alexion Pharmaceuticals (NASDAQ: ALXN), AbbVie (NYSE: ABBV), Aimmune Therapeutics (NASDAQ: AIMT), and bluebird bio (NASDAQ: BLUE) came out on top in EvaluatePharma's ranking of the top five new drug launches expected this year. Risankizumab (AbbVie) Upadacitinib wasn't AbbVie's only immunology drug to make EvaluatePhar... | Risankizumab (AbbVie) Upadacitinib wasn't AbbVie's only immunology drug to make EvaluatePharma's top five list. Alexion Pharmaceuticals (NASDAQ: ALXN), AbbVie (NYSE: ABBV), Aimmune Therapeutics (NASDAQ: AIMT), and bluebird bio (NASDAQ: BLUE) came out on top in EvaluatePharma's ranking of the top five new drug launches ... |
24,997 | 2019-05-15 00:00:00 UTC | Health Care Sector Update for 05/15/2019: ABBV,ACB,ACB.TO,ECOR,IMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-05-15-2019%3A-abbvacbacb.toecorimgn-2019-05-15 | null | null | Top Health Care Stocks
JNJ +0.12%
PFE +1.36%
ABT +0.85%
MRK +0.39%
AMGN +1.38%
Health care stocks still were rising, with the NYSE Health Care Index adding almost 0.6% in value late Wednesday while shares of health care companies in the S&P 500 were up slightly more than 0.4% as a group. The Nasdaq Biotechnology index ... | Among health care stocks moving on news: (+) AbbVie (ABBV) pushed higher this afternoon, erasing a more than 1% decline earlier in the session after the US Food and Drug Administration approved a combination of its Venclexta drug candidate with the obinutuzumab monoclonal antibody to treat previously untreated patients... | Among health care stocks moving on news: (+) AbbVie (ABBV) pushed higher this afternoon, erasing a more than 1% decline earlier in the session after the US Food and Drug Administration approved a combination of its Venclexta drug candidate with the obinutuzumab monoclonal antibody to treat previously untreated patients... | Among health care stocks moving on news: (+) AbbVie (ABBV) pushed higher this afternoon, erasing a more than 1% decline earlier in the session after the US Food and Drug Administration approved a combination of its Venclexta drug candidate with the obinutuzumab monoclonal antibody to treat previously untreated patients... | Among health care stocks moving on news: (+) AbbVie (ABBV) pushed higher this afternoon, erasing a more than 1% decline earlier in the session after the US Food and Drug Administration approved a combination of its Venclexta drug candidate with the obinutuzumab monoclonal antibody to treat previously untreated patients... |
24,998 | 2019-05-12 00:00:00 UTC | Is It Finally Time to Buy Gilead Sciences? | ABBV | https://www.nasdaq.com/articles/it-finally-time-buy-gilead-sciences-2019-05-12 | null | null | In 2014, Gilead Sciences (NASDAQ: GILD) revolutionized hepatitis C treatment with a new class of drugs that functionally cured the disease, virtually eliminating the risk of life-threatening liver failure. The drugs were so game-changing that they -- and the drugs that followed in their footsteps -- quickly became bill... | Curing patients has shrunk the addressable market, and competition from AbbVie (NYSE: ABBV) has caused a profit-busting price war. In 2014, Gilead Sciences (NASDAQ: GILD) revolutionized hepatitis C treatment with a new class of drugs that functionally cured the disease, virtually eliminating the risk of life-threatenin... | Curing patients has shrunk the addressable market, and competition from AbbVie (NYSE: ABBV) has caused a profit-busting price war. So far, the company's struggled to replace declining hepatitis C revenue, but Gilead Sciences' first-quarter financials suggest its struggle may be ending. Investors shouldn't expect much t... | Curing patients has shrunk the addressable market, and competition from AbbVie (NYSE: ABBV) has caused a profit-busting price war. A three-drug combination therapy, Biktarvy racked up $793 million in sales last quarter, up from $35 million in Q1 2018, which contributed to a U.S. HIV revenue increase of 19% year over ye... | Curing patients has shrunk the addressable market, and competition from AbbVie (NYSE: ABBV) has caused a profit-busting price war. Following positive results from phase 3 trials evaluating filgotinib, a selective JAK-inhibitor licensed from Galapagos, the company plans to file for European approval in rheumatoid arthri... |
24,999 | 2019-05-08 00:00:00 UTC | WisdomTree U.S. Quality Dividend Growth Fund Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/wisdomtree-u.s.-quality-dividend-growth-fund-experiences-big-outflow-2019-05-08 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the WisdomTree U.S. Quality Dividend Growth Fund (Symbol: DGRW) where we have detected an approximate $73.6 million dollar outflow -- that's a 2.7% decrease week over week (from 63,800,000 to 62... | Among the largest underlying components of DGRW, in trading today Apple Inc (Symbol: AAPL) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Las Vegas Sands Corp (Symbol: LVS) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of DGRW, in trading today Apple Inc (Symbol: AAPL) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Las Vegas Sands Corp (Symbol: LVS) is up by about 0.3%. For a complete list of holdings, visit the DGRW Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of DGRW, in trading today Apple Inc (Symbol: AAPL) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Las Vegas Sands Corp (Symbol: LVS) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of DGRW, in trading today Apple Inc (Symbol: AAPL) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Las Vegas Sands Corp (Symbol: LVS) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.